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ABSTRACT 
 
 
 The tripartite motif-containing (TRIM) proteins have emerged as a new class of host 
antiviral restriction factors, with several demonstrating roles in regulating innate antiviral 
responses. Of >70 known TRIMs, TRIM56 inhibits replication of bovine viral diarrhea 
virus, a ruminant pestivirus of the family Flaviviridae, but has no appreciable effect on 
VSV, a rhabdovirus. We have also shown that TRIM56 forms a complex with the Toll-
like receptor-3 (TLR3) adaptor, TRIF, via its C-terminal residues 621-750, and augments 
TLR3-mediated interferon (IFN) induction and establishment of an antiviral state. Yet, 
TRIM56’s antiviral spectrum and the precise underlying mechanisms by which TRIM56 
executes its direct antiviral functions and modulates TLR3 signaling remain undefined. 
Also unclear are the molecular determinants governing the direct and indirect antiviral 
activities of TRIM56.  
 
Herein, in Chapter 3, I show that TRIM56 poses a barrier to infections by yellow 
fever virus (YFV), dengue virus serotype-2 (DENV2), and human coronavirus virus 
(HCoV)-OC43. Moreover, I demonstrate that TRIM56’s anti-flavivirus effects required 
both the E3 ligase activity that lies in the N-terminal RING domain and the integrity of its 
C-terminal portion, while the restriction of HCoV-OC43 relied upon the TRIM56 E3 
ligase activity alone. Furthermore, TRIM56 was revealed to impair YFV and DENV2 
propagation by suppressing intracellular viral RNA accumulation but to compromise 
HCoV-OC43 infection at a later step in the viral life cycle, suggesting that distinct 
TRIM56 domains accommodate differing antiviral mechanisms. Next, in Chapter 4, I 
show TRIM56 puts a check on replication of influenza A and B viruses in cell culture. 
Interestingly, the anti-influenza activity was independent of the E3 ligase activity, B-box, 
or coiled-coil domains. Rather, deletion of a 63-residue long, C-terminal tail portion of 
TRIM56 abrogated the antiviral function. Moreover, expression of this short C-terminal 
segment curtailed the replication of influenza viruses as effectively as that of full-length 
TRIM56. Mechanistically, TRIM56 was found to specifically impede intracellular 
influenza virus RNA synthesis. Altogether, TRIM56 is a versatile antiviral host factor 
that confers resistance to YFV, DENV2, HCoV-OC43 and influenza viruses through 
overlapping and distinct molecular determinants. Last, in Chapter 5, I report TRIM56 
over-expression promoted activation of NF-κB following TLR3 engagement but not that 
induced by TNF-α- or IL-1β. Next, I observed that the coiled-coil domain and residues 
431-610, but not the B-box or residues 355-433, were required for TRIM56 augmentation 
of TLR3-dependent IFN-β promoter activation. Furthermore, alanine screening 
mutagenesis suggested the S469A+S471A+S475A triple mutant and S471A, S475A and 
S710A single mutant failed to enhance TLR3 signaling. In line with this, S471A, S475A 
and S710A, as well as the coiled-coil deletion mutant lost the ability to enhance poly-I:C-
mediated establishment of an antiviral state compared with wild-type TRIM56. 
Collectively, these data reveal novel insights into the mechanism of TRIM56 
augmentation of TLR3-dependent antiviral response and highlight a role for TRIM56 
scaffolding and phosphorylation in positive regulation of TLR3 signaling.  
 v 
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CHAPTER 1.    INTRODUCTION 
 
 
Background 
 
 
TLR3-mediated Innate Immune Responses against Positive-strand RNA Viruses 
 
In response to viral invasion, the innate immune system plays a critical role in 
recognizing intruding viral pathogens and inducing antiviral or inflammatory responses, 
thereby facilitating adaptive immune responses (1-4). Among the multilayered 
mechanisms of host intrinsic defense, germline-encoded pattern recognition receptors 
(PRRs) present on innate immune sentinel cells, such as Toll-like receptors (TLRs) and 
retinoic-inducible gene-I (RIG-I)-like receptors, play important parts in sensing viral 
nucleic acids or replicative intermediates produced during viral replication as a major 
class of viral pathogen-associated molecular pattern (PAMP). Those receptors initiate  
downstream intracellular signaling cascades that culminate in the production of 
interferons (IFNs) and pro-inflammatory cytokines/chemokines. Therefore, the innate 
immune responses constitute a primary and fundamental component of host defense in 
the immediate-early phase of viral infections (2-5). 
 
Among various host PRRs, TLRs represent the first type to be discovered and 
characterized. There are 10 human TLRs (TLR1-TLR10) and 12 murine TLRs (TLR1-9 
and TLR11-13) (4). Structurally speaking, all TLRs are type I transmembrane proteins 
consisting of N-terminal leucine-rich repeat-containing ectodomain which interacts with 
and recognizes PAMPs, a transmembrane domain, and a C-terminal Toll-interleukin-1 
receptor (IL-1R) homology (TIR) domain which is responsible for activation of signaling 
transduction via interacting with their adaptor proteins (1,2,4). There are only two types 
of adaptors for TLRs-mediated signal transduction – either myeloid differentiation 
primary response 88 (MyD88) or TIR-domain-containing adaptor inducing interferon-β 
(TRIF) (4). Remarkably, TLR3 only signals through TRIF while the other TLRs signal 
through MyD88, with TLR4 using both adaptors. TLRs also vary on cellular localization 
and the ligands (PAMPs) to be sensed (4). For example, TLR2 and TLR4 on the cell 
surface are responsible for recognition of viral proteins. TLR3, TLR7, TLR8 and TLR9 
localized in endosomes sense intracellular viral nucleic acids (1). Specifically, TLR3, 
TLR7/TLR8 and TLR9 recognize viral dsRNA, ssRNA and unmethylated CpG DNA, 
respectively. Engagement of TLRs with their cognate ligands activates distinct, 
intracellular signaling pathways through the adaptor proteins, which relay signals to 
downstream IκB (IKK) and IKK-related kinases (2-4). Subsequently, the classical IKKs 
(IKKα/IKKβ/IKKγ) activate the transcription factor NF-κB for downstream pro-
inflammatory cytokine production, while the IKK-related kinases (TBK1/IKKε) 
phosphorylate and activate IFN-regulatory factors IRF3 and/or IRF7 which are critical 
for induction of type I IFNs (IFN-β and IFN-α). IFNs further induce hundreds of IFN-
stimulated genes (ISGs) to establish an antiviral state restricting viral propagation and 
dissemination (1-4). 
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Among different TLRs, TLR3 represents the first one to be well characterized which 
senses nucleic acid, i.e., dsRNA, and TLR3 as an essential PRR has been demonstrated to 
play important roles in sensing and fending off positive-strand RNA viruses (1,2,4). For 
instance, TLR3 is able to sense the infection by dengue virus and plays a protective role 
against West Nile Virus infection (6,7). TLR3 signaling also has a protective effect on the 
heart after encephalomyocarditis virus-induced injury and decreases the virulence of this 
picornavirus (8). However, facing the host innate immune system, numerous viruses have 
evolved to acquire different strategies to circumvent or counteract with the TLR-
dependent host defense responses (4). For instance, vaccinia viruses encode two proteins, 
A46R and A52R, which associate with TLR adaptor proteins and TRAF6, respectively, 
thereby blocking TLR signaling (9,10). Another appealing example is hepatitis C virus 
which utilizes its NS3/4A serine protease to cleave TRIF, the sole adaptor for TLR3, to 
compromise TLR3-mediated host antiviral immunity (11).  
 
 
Host Responses to Influenza Virus Infection  
 
Classified within the family Orthomyxoviridae, influenza A and B viruses (IAV and 
IBV) are important respiratory pathogens responsible for significant morbidity and 
mortality worldwide (12-15). Apart from typical influenza diseases, influenza virus 
infection may trigger severe influenza-related complications, for instance, cardiovascular 
diseases (CVDs) (12,13). This is especially true for the elderly who represents an 
overlapping high-risk population for both influenza virus infections and CVDs (16-18). 
Remarkably, epidemiological studies have established an association of IAV infection 
with CVDs (16-18). Influenza viruses primarily infect lungs and respiratory tract but can 
trigger cardiac complications, such as atherosclerosis and acute myocardial infarction 
(16-18). Influenza vaccines are commonly considered to be an effective measure to 
prevent influenza infection. However, despite its protective effects shown on some CVD 
patients, influenza vaccine efficacy declines with age: from approximately 59% in adults 
aged 18-65 years to 49% in the 65+ population (19). What’s worse, the elderly with 
underlying CVDs are particularly vulnerable to unanticipated new influenza subtypes that 
emerge. These issues underscore the importance of developing novel and broad-spectrum 
anti-influenza approaches to provide high-risk populations with better CVD prevention 
(18,19). 
 
Influenza viruses are characterized by segmented, negative-strand RNA genomes in 
the viral particle core, which are encapsidated by nucleoprotein (NP) and bound with 
polymerase proteins, thus forming viral ribonucleoprotein (vRNP) complexes (15,20,21). 
Influenza virus life cycles are featured by the dependence on nuclear functions, which is 
rare to RNA viruses (15). After cell entry, trafficking of the viral genome into the nucleus 
is an active process dependent on the nuclear import machinery. Although the major viral 
components of IAV vRNP complexes all possess nuclear localization sequences (NLSs), 
the signals on NP are believed to be both sufficient and necessary for recognition and 
pick-up by cellular importins (15,20,21). Among the localization signals, the strongest 
unconventional NLS-1 of NP is found at its extreme N-terminus, a weaker, bipartite 
NLS-2 is present in the middle of NP (residues 198-216), and a nuclear accumulation 
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sequence (NAS) has been detected at the C-terminus (residues 336-345). These NLSs on 
NP are also important for nuclear import of this viral protein after translation (15,20,21). 
 
In response to influenza invasion, the innate immune system represents a front line of 
host defense armed with multi-layered mechanisms. Of these, PRRs such as TLRs and 
RIG-I-like receptors, sense viral nucleic acids, a major class of viral PAMPs triggering 
intracellular signaling pathways that activate IRF3 and NF-κB, which play pivotal roles 
in the production of IFNs and pro-inflammatory cytokines/chemokines (22-24). Influenza 
virus, in return, inhibits IRF3 activation by its non-structural protein (NS)-1 to decrease 
IFN generation whereas it exploits activated NF-κB to regulate its viral RNA (vRNA) 
synthesis, develop inflammation and induce synthesis of ectopic trypsins and matrix 
metalloproteinases (MMPs), thereby triggering cardiac injuries (22-26). IAV structural 
proteins, e.g. NP, can also augment NF-κB signaling, the molecular mechanisms 
underlying which remain elusive (27). 
 
 
TRIMs: Novel Players in Antiviral Innate Immunity 
 
The tripartite motif-containing (TRIM) protein family consists of more than 70 
members in human beings. It is previously known that TRIMs play essential roles in a 
broad array of biological processes, including proliferation, differentiation and apoptosis. 
Over the past decade, people have begun to appreciate important roles of TRIM family 
members in antiviral innate immunity (28-30). As suggested by their names, there are 
three highly conserved domains in TRIMs’ N-terminal RBCC motif, including RING, 
one or two B-boxes and coiled-coil domains. In contrast, TRIMs C-terminal tails vary 
with different domains, based on which this protein family can be divided into 11 
subfamilies (Figure 1-1) (31). Functionally speaking, thanks to the RING domains, 
TRIMs have been believed to be a large group of E3 ubiquitin (Ub) ligases. The B-box 
domains of TRIMs are regarded as zinc-binding motifs while coiled-coil domains play 
important roles in self-association and oligomerization of TRIM molecules, thereby 
acting as scaffolds to recruit and form multi-protein signaling complexes (28-31).  
 
Roles of TRIMs in restriction of retroviruses are the first to be characterized, as 
exemplified by TRIM5α which suppresses HIV-1 multiplication by catalyzing poly-
ubiquitination of the viral capsid and blocking the viral uncoating step (28-31). A 
growing number of TRIMs have been progressively found to play direct antiviral roles in 
host restriction of viruses of other families by targeting important steps in the viral life 
cycle (Figure 1-2) (28-32). For example, TRIM22 polyubiquitinates IAV NP and targets 
it for proteasome-dependent degradation (33). In addition, TRIM56 was identified as a 
pleiotropic host antiviral factor restricting distinct RNA viruses via overlapping and 
distinct molecular determinants, including human coronavirus-OC43, IAV and 
Flaviviridae members (34-36). 
 
Intriguingly, some TRIMs are also able to positively or negatively modulate the 
innate antiviral immune signaling pathways, thereby impacting IFN induction. On one 
hand, it is reported that approximately more than 30 TRIMs act at multiple levels of  
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Figure 1-1. TRIM family members and their subfamily classification. 
TRIM protein family members can be divided into up to 11 subfamilies based on the 
diversity of their C-terminal domain composition. 
 
 5 
 
 
Figure 1-2. Roles of TRIMs in innate antiviral immunity. 
(Left) TRIMs exhibit direct antiviral activity by targeting important steps of the viral life 
cycle. TRIM1/8/11/31 inhibit viral entry step. TRIM5α prevents uncoating step of HIV-1. 
TRIM11/22/28/32 suppress retroviral gene transcription. TRIM56 restricts intracellular 
viral RNA replication of Flaviviridae members and influenza viruses. TRIM11/22/26/32 
block virus packaging/release steps. (Right) TRIMs play important roles in modulation of 
PRR-mediated innate immune signaling pathways. TRIM25 ubiquitinates and activates 
RIG-I, thereby promoting IFN induction. TRIM56 potentiates TLR3 signaling by 
forming a complex with TRIF, the adaptor for TLR3. TRIM27 inhibits IKK activation. 
TRIM21/28 down-regulate IRF7 activation. 
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innate immune signaling pathways to enhance antiviral responses (37). A prime example 
among this group of TRIMs is E3 ligase TRIM25 which substantially augments RIG-I-
mediated signaling pathway and IFN production by ubiquitinating and activating RIG-I 
(38). Another example is TRIM56, which has been demonstrated to significantly enhance 
TLR3-mediated signaling and establishment of an antiviral state by forming a complex 
with TRIF (39). On the other, a handful of TRIMs have been identified as negative 
regulators of PRR signaling, such as TRIM21 and TRIM27 down-regulating IKK activity 
and IRF7 activation, respectively (29,30). 
 
 
Statement of Purpose 
 
      The tripartite motif-containing (TRIM) proteins have emerged as a new class of host 
antiviral restriction factors, with several demonstrating roles in regulating innate antiviral 
responses. Of >70 known TRIMs, TRIM56 inhibits replication of bovine viral diarrhea 
virus, a ruminant pestivirus of the family Flaviviridae, but has no appreciable effect on 
VSV, a rhabdovirus. We have also shown that TRIM56 forms a complex with the Toll-
like receptor-3 (TLR3) adaptor, TRIF, via its C-terminal residues 621-750, and augments 
TLR3-mediated interferon (IFN) induction and establishment of an antiviral state. Yet, 
TRIM56’s antiviral spectrum and the precise underlying mechanisms by which TRIM56 
executes its direct antiviral functions and modulates TLR3 signaling remain undefined. 
Also unclear are the molecular determinants governing the direct and indirect antiviral 
activities of TRIM56. The goal of this dissertation research has been to dissect the 
molecular determinants dictating TRIM56’s novel antiviral activities against positive- 
and negative-strand RNA viruses and TRIM56-mediated positive regulation of the TLR3 
antiviral signaling pathway as well as the molecular mechanisms by which TRIM56 
executes its direct antiviral and signaling regulation functions. 
 
? The objective of Chapter 3 is to dissect the molecular determinants dictating 
TRIM56’s novel antiviral activities against medically important, positive-strand 
RNA viruses and the molecular mechanisms by which TRIM56 executes its direct 
antiviral functions against these viruses. 
 
? The objective of Chapter 4 is to study the molecular determinants dictating 
TRIM56’s novel antiviral activities against negative-strand RNA viruses and the 
molecular mechanisms by which TRIM56 exhibits its direct antiviral activities 
against these viruses. 
 
? The objective of Chapter 5 is to investigate the molecular determinants dictating 
TRIM56-mediated positive regulation of the TLR3 antiviral signaling pathway 
and the molecular mechanisms by which TRIM56 executes its signaling 
regulation functions. 
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CHAPTER 2.    METHODS AND MATERIALS1 
 
 
Plasmids 
 
To construct C-terminally V5-tagged mouse TRIM56 (here referred to as mTRIM56 
or mT56) expression vector (designated pEF6-mTRIM56-V5His), the cDNA encoding 
mTRIM56 was amplified by PCR using the primers 5’-
GAAGATCTATGAACTCCAAAGACTCCTCCCCAAC-3’ (forward) and 5’-
GAATTCGCTGTCAGGAAACCTGACCCTAAAGA-3’ (reverse), and subsequently  
ligated into pEF6/V5-His TOPO (Invitrogen). The plasmid encoding N-terminal 2×HA-
tagged human TRIM56 in the pcDNA5/FRT/TO backbone (Invitrogen) has been 
described previously and designated as pcDNA5/FRT/TO-HA-TRIM56 (39). Plasmid 
vectors encoding various mutant (Mut) forms of TRIM56 were constructed from 
pcDNA5/FRT/TO-HA-TRIM56 by QuikChange site-directed mutagenesis (Stratagene). 
The vectors encoding C-terminally V5-tagged wild-type (WT) TRIM56 (designated 
pcDNA3.1-TRIM56-V5His) and its E3 ligase-null mutant (Mut) CC21/24AA and various 
deletion mutants were described elsewhere (34). S469A, S471A, S475A, S710A or 
S710D single mutation, or S469A+S471A+S475A triple mutations were introduced into 
pcDNA3.1-TRIM56-V5His, and S689A into pEF6-mTRIM56-V5His by inverse PCR. 
The mutagenesis primers used are listed in Table 2-1. The gene fragments containing 
mutant TRIM56 (S469A, S471A, S475A, S710A, S710D or S469A+S471A+S475A) in 
pcDNA3.1 backbone were then swapped to pcDNA5/FRT/TO-HA backbone (Invitrogen) 
and the resultant vectors were designated pcDNA5/FRT/TO-HA-TRIM56 Mut. The 
coding sequences of the C-terminal-tail 135 and 63 residues (CTT135 and CTT63) of 
TRIM56 were amplified from a plasmid encoding full-length human TRIM56 via PCR 
and subsequently ligated into the pcDNA5/FRT/TO (Invitrogen) vector to generate the 
pcDNA5/FRT/TO-HA-TRIM56-CTT135 and -CTT63 constructs, respectively. In these 
constructs TRIM56-CTT135 and CTT63 were expressed as peptides fused in frame to an 
N-terminal 2xHA epitope tag. A vector designated pCX4pur-FH-TRIM56 was 
constructed by swapping the cDNA fragment encoding TRIM56 from pcDNA5/FRT/TO 
backbone to pCX4pur-Flag-HA vector to ensure expression of TRIM56 fused with N-
terminal Flag-HA tandem tags (FH-TRIM56). The identities of all plasmids were 
confirmed by DNA sequencing. pFlag-TRIF-mRHIM encoding a Flag-tagged, 
constitutively active form of human TRIF (here referred to as Flag-TRIFSA) has been 
described elsewhere (39). pCMV1-Flag-TLR3 was a gift from Ruslan Medizhitov (Yale 
University). 
__________________ 
 
1 Adapted with permission. Liu B, Li NL, Wang J, Shi PY, Wang T, Miller MA, Li K. 
2014. Overlapping and distinct molecular determinants dictating the antiviral activities of 
TRIM56 against flaviviruses and coronavirus. J Virol 88:13821-13835; Liu B, Li NL, 
Shen Y, Bao X, Fabrizio T, Elbahesh H, Webby RJ, Li K. The C-terminal Tail of 
TRIM56 Dictates Antiviral Restriction of Influenza A and B Viruses by Impeding Viral 
RNA Synthesis. J Virol 2016. pii: JVI.03172-15. 
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Table 2-1. Mutagenesis primers for human (hT56) or mouse (mT56) TRIM56. 
 
  Mutations Primer sequences (5’ ? 3’) 
  hT56-S469A Forward: ATATCCCGGGAGCCCAGCCCAG 
Reverse: CGCCTTGAGCCTGCCTTTGAAC 
 
  hT56-S471A Forward: GCTCGAGAGCCCAGCCCAGCCCT 
Reverse: AATTGACTTGAGCCTGCCTTTGA 
 
  hT56-S475A Forward: GCTCCAGCGCTGGGGCCGAATCT 
Reverse: GGGCTCCCGGGAAATTGACTTGA 
 
  hT56-S710A Forward: GCTCTCCTTGGAGACTTCCTG 
Reverse: TCCCTTCGGGTCCAGGATCAC 
 
  hT56-S710D Forward: GATCTCCTTGGAGACTTCCTG 
Reverse: TCCCTTCGGGTCCAGGATCAC 
 
  hT56-
S469A+S471A+S475A 
Forward: 
GAGCCCGCTCCAGCCCTGGGGCCGAAT 
Reverse:  
TCGAGCAATAGCCTTGAGCCTGCCTTTGA 
 
  mT56-S689A Forward: GCTCTTCTTGGTGACTTCCTAAC 
Reverse: TCCCTTGGGATCCAGTATCAC 
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The plasmid pcDNA6-YFVpro contained the full-length NS2B-NS3 coding sequence 
of yellow fever virus (YFV)-17D in pcDNA6/V5-HisB backbone (40). Recombinant 
plasmids encoding the TSV01 strain of dengue virus-2 (DENV2) replicon (pACYC-TSV-
Rep-WT) and its replication-deficient, NS4B P104R mutant (pACYC-TSV-NS4B-
P104R) were gifts from Pei-Yong Shi (41). The full-length N coding sequence of HCoV-
OC43 was amplified from cDNA of virally infected BSC-1 cells and ligated into 
pEF6/V5-His-TOPO (Invitrogen), to generate the pEF6-OC43-N-V5His construct in 
which the N gene is fused in frame to C-terminal V5-His6 epitope tags. The identities of 
all plasmids were confirmed by DNA sequencing. 
 
Plasmids for luciferase (luc) reporter-based IAV RNA synthesis assay were gifts from 
Richard Webby (St. Jude Children’s Research Hospital), which include polymerase II-
driven pHW plasmids expressing PB2, PB1, PA and NP of influenza A/PR/8/34 virus, 
and a polymerase I-driven luc reporter plasmid (pHY-Luci), which expresses in the 
negative sense the firefly luciferase flanked by noncoding sequences from the IAV matrix 
(M) segment (42). 
 
 
Cell Lines 
 
Human embryo kidney (HEK) 293, 293-TLR3 cells (HEK293 cells constitutively 
expressing human TLR3), HeLa, mosquito C6/36, African green monkey kidney Vero, 
Vero-E6, BSC-1 and Madin-Darby canine kidney (MDCK) epithelial cell lines were 
maintained in Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine 
serum, 100 U/ml of penicillin and 100 μg/ml streptomycin. Madin-Darby bovine kidney 
(MDBK) and its derivative cells were grown in medium containing horse serum in lieu of 
FBS. Human hepatoma Huh7.5-TLR3 cells with TLR3 stable expression (Huh7.5-TLR3) 
were described previously (43). HEK293-T3Y-FH-T56 cells constitutively expressing 
FH-TRIM56 were generated by transducing HEK293-TLR3-YFP (293-T3Y, a gift from 
Kate Fitzgerald, University of Massachusetts) cells with replication-incompetent 
retroviruses carrying FH-T56 in pCX4pur backbone (pCX4pur-FH-TRIM56), followed 
by stable selection with puromycin. MDBK cell pools stably expressing C-terminal Flag-
tagged, WT or various mutant human TRIM56 (MDBK-T56 WT/Mut), or an empty 
vector (MDBK-Bsr), have been described elsewhere (34). Human osteosarcoma U2OS 
cell pools stably expressing TRIM56-Flag (referred to as U2OS-T56) and control U2OS-
Bsr cells expressing an empty retroviral vector (pCX4-Bsr) were developed by retroviral 
gene transfer, followed by stable selection with blasticidin, as described (34). 
 
HEK293 cells constitutively expressing WT or the E3 Ub ligase-deficient 
CC21/24AA mutant (Cys21 and Cys24 in the RING domain substituted with alanines) 
TRIM56 (designated as 293-T56 and 293-T56-CC21/24AA, respectively), were 
generated by transducing HEK293 cells with replication-incompetent retroviruses 
carrying C-terminal Flag-tagged WT and CC21/24AA mutant TRIM56 in pCX4bsr 
backbone, respectively, followed by stable selection with blasticidin (35).  
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HeLa-Flp-In T-REx-ACE2 (FitA2) cells with tetracycline (tet)-inducible expression 
of HA-tagged, WT and various mutant versions of TRIM56, have been described and 
designated as HeLa-FitA2-T56 WT/Mut (39). Herein we created the HEK293 cell lines 
conditionally expressing WT or various mutant versions of TRIM56 (different deletion 
mutants, or CTT135, CTT63 or S469A, S471A, S475A, S710A or 
S469A+S471A+S475A) using the Flp-In T-REx (FIT) expression system (Invitrogen) 
following the manufacturer’s recommended protocol. In brief, 293-FIT cells were co-
transfected with pOG44 encoding the Flp recombinase and pcDNA5/FRT/TO-HA-
TRIM56 or the indicated TRIM56 mutants in pcDNA5/FRT/TO-HA backbone at 9:1 
ratio, followed by stable selection of cells in media containing 200 μg/ml of hygromycin. 
The resultant cell lines were named 293-FIT-T56 or 293-FIT-T56-Mut, respectively. To 
induce the HA-TRIM56 (or mutant HA-TRIM56) expression in 293-FIT- and HeLa-
FitA2-derived cells, cells were cultured in tet-containing medium for 48 h.  
 
 
Viruses, Viral Infections, Replication Assays and Miscellaneous Reagents 
 
YFV-17D (NR-115; BEI Resources) and DENV2 (Thailand 16681 strain) were 
propagated in Vero-E6 and C6/36 cells, respectively. Viral stock of HCoV-OC43 (ATCC 
VR-1558) was prepared in BSC-1 cells. EMCV (ATCC VR-1314, provided by Lawrence 
Pfeffer) was propagated in Vero cells. Viral stocks of influenza A/PR/8/34 (H1N1) virus 
(ATCC VR-1469) and B/Florida/4/06 (Yamagata-lineage) virus (provided by Richard 
Webby) were propagated and viral titers determined in MDCK cells. A recombinant 
vesicular stomatitis virus (VSV) expressing firefly luciferease, VSV-Luc, was a gift from 
Sean Whelan (Harvard Medical School). VSV-Luc stocks were prepared in Vero cells 
(44). Human metapneumovirus (hMPV) stocks were propagated and viral titers 
determined in LLC-MK2 cells (45). Sendai virus (SeV, Cantell strain) was purchased 
from Charles River Laboratories and used to infect cells at 100 HAU/ml for 12 h. Viral 
infections of cells were conducted as described (34,40,46-48). Progeny infectious virus 
titers in cell-free culture supernatants were determined by endpoint dilution-based 50% 
tissue culture infective dose (TCID50) assays in 96-well plates (43,49). Specifically, 
titration of YFV and EMCV was performed on Vero-E6 cells while HCoV-OC43 
titration on BSC-1 cells. Cytopathic effect (CPE) was recorded and used for calculation 
of virus yield on 7 days post-infection (dpi) for YFV-17D and HCoV-OC43, and on 3 dpi 
for EMCV, respectively. Because infection by DENV2 does not cause obvious CPE, 
titration of virus yield was performed on Vero cells on 3 dpi using immunofluorescence 
staining to score prM-positive cell wells. TCID50 assays was also performed to determine 
progeny infectious virus titers of IAV/IBV in cell-free culture supernatants, on 
monolayers of MDCK cells (34,46,48). Cytopathic effect was recorded and used for 
calculation of infectivity at 24 hours postinfection (hpi) for IAV and 48 hpi for IBV, 
respectively. All resultant viral titers were expressed as TCID50/ml. 
 
Poly-I:C (a dsRNA surrogate) was obtained from Sigma. To stimulate cells, poly-I:C 
(pIC) was added into culture medium at a final concentration of 20 μg/ml. TNF-α and IL-
1β were used at a final concentration of 10 ng/ml for cell stimulation. 
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Transient Replicon Assay 
 
The Renilla luciferase-encoding, WT and NS4B P104R mutant DENV2 replicons 
were synthesized from Cla I-linearized plasmid templates by in vitro transcription as 
described elsewhere (41). 293-FIT-T56 cells cultured in the absence or presence of tet 
(3×105 cells) were transfected with 1 μg of WT or the NS4B mutant replicon RNA using 
DMRIE-C (Invitrogen) as per instructions from the manufacturer. At 4 h post 
transfection, cells were split and seeded in 24-well plates. At various time points post 
transfection, cells were lysed in 200 μl 1× lysis buffer (Promega). Thirty microliters of 
cell lysates were subject to Renilla luciferase assay (Promega). 
 
 
RNA Interference 
 
For stable knockdown of human TRIM56, we used a short hairpin RNA (shRNA) 
targeting the coding region of human TRIM56 gene inserted in the pLKO.1-puro vector 
that was purchased from Openbiosystems (referred to as shT56-094). The target sequence 
is: 5’-GCAGCAGAATAGTGTGGTAAT-3’ (34-36).  In addition, for stable knockdown 
of endogenous human TRIM56 without impact on the expression of exogenously 
introduced TRIM56, I used another shRNA which specifically targets the 3’ untranslated 
region (UTR) region of TRIM56 gene and was inserted in the pLKO.1-puro vector 
(referred to as shT56 #093). The target sequence is: 5’-
CGTCTTCTAGTGTGTGAGAAT-3’. As a negative control, a non-targeting scrambled 
shRNA, also cloned in pLKO.1-puro (Addgene #1864), was used (34-36). The shRNAs 
were packaged into replication-incompetent lentiviral particles in 293FT cells, and 
subsequently used to infect indicated cell lines. Following selection in medium 
containing 2-5 μg/ml of puromycin for 2-3 weeks, surviving cell colonies were pooled 
for further analysis. For transient knockdown of endogenous TRIM56 in 293-FIT-T56-
WT/Mut cells without down-regulating the expression of exogenously introduced HA-
TRIM56-WT/Mut, I employed an siRNA (Fisher Scientific) that specifically targets the 
3’ UTR of human TRIM56 transcript (35). This siRNA had a target sequence of 5’-
GCCGCTGCTATATAGTTTA-3’, and was transfected into cells at a final concentration 
of 100 nM by Lipofectamine 2000 (Invitrogen) as per the manufacturer’s instructions. To 
silence the expression of STING, I transfected cells with a mixture of two shRNAs 
targeting the coding region of human STING transcript (TRCN0000160281 and 
TRCN0000163296, Openbiosystems). To knockdown TRIF or RIG-I, I used synthetic 
siRNAs that have previously been described (11,50). The target sequences were: TRIF-
1077, GAAGATACCACCTCTCCAA; RIG-I, GGAAGAGGTGCAGTATATT. 
 
MDBK cells with stable knockdown of endogenous bovine TRIM56 (boT56) have 
been described elsewhere (34). To knock down exogenously expressed human TRIM56 
in MDBK-T56 cells, shT56-#094 or a non-targeting scrambled shRNA (as a negative 
control) were packaged into replication-incompetent lentiviral particles in HEK293FT 
cells, and subsequently used to transduce MDBK-T56 cells, respectively (36). Following 
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selection in medium containing 2-5 μg/ml of puromycin for 2-3 weeks, survived cell 
colonies were pooled for further analysis. 
 
 
RNA Analyses 
 
Extraction of total cellular RNA by TRIzol, cDNA synthesis by reverse transcription 
and quantitative PCR (qPCR) were implemented as described elsewhere (34,51). The 
following primers were used: ISG56 and 28S (39); IFN-β (51); IL29, 5’-
GAAGAGTCACTCAAGCTGAAAAACTG-3’ (forward) and 5’-
GAGAAGCCTCAGGTCCCAATT-3’ (reverse); TRIM56 coding region (34); TRIM56 
3’UTR, 5’-CCGAGGACATTTTCCTGAAG-3’ (forward) and 5’-
AGTTAAGGTCACGCCACCAC-3’ (reverse); TRIF, 5’-
GTGGAGGAAGGAACAGGACA-3’ (forward) and 5’-
TGAGTAGGCTGCGTTCAGTG-3’ (reverse); RIG-I, 5’-
GGACGTGGCAAAACAAATCAG-3’ (forward) and 5’-
ATTGTGATCTCCACTGGCTTTGA-3’ (reverse); STING, 5’ 
TCAAGGATCGGGTTTACAGC-3’ (forward) and 5’- 
TGGCAAACAAAGTCTGCAAG-3’ (reverse); YFV NS2B region, 5’-
TGAACAAGGGGAGTTCAAGC-3’ (forward) and 5’-
AGGACCAGCAGAAGAGCAAA-3’ (reverse); HCoV-OC43 N gene, 5’-
CGATGAGGCTATTCCGACTAGGT-3’ (forward) and 5’-
CCTTCCTGAGCCTTCAATATAGTAACC-3’(reverse) (52). The relative abundance of 
each target was normalized to that of 28S rRNA. Copy numbers of YFV and HCoV-
OC43 RNAs were calculated based on standard curves generated using serially diluted 
pcDNA6-YFVpro and pEF6-OC43-N-V5His DNA, respectively.  
 
To analyze the abundance of three different influenza viral RNA species, RT was 
performed using strand- and sense-specific oligonucleotides for vRNA, anti-genomic 
complementary RNA (cRNA) and mRNA as previously described (26). A 28S-specific 
primer (5’ CTTAACGGTTTCACGCCCTC 3’) was also included in the RT reaction 
mixture for vRNA or cRNA analysis. Subsequently the following primers were used for 
qPCR: M segment of influenza A/PR/8/34 virus, 5’ GACCRATCCTGTCACCTCTGAC 
3’ (forward) and 5’ AGGGCATTYTGGACAAAKCGTCTA 3’ (reverse); and 
hemaglutinin (HA) segment of influenza A/PR/8/34 virus, 5’ 
GGCCCAACCACAACACAAAC 3’ (forward) and 5’ AGCCCTCCTTCTCCGTCAGC 
3’ (reverse). The qPCR primers for measuring mRNA abundance of SeV P gene are, 5’-
CTCTGGGAGAACAAGCAAGC-3’ (forward) and 5’- 
TCGCCCAGATCCTGAGATAC-3’ (reverse). The relative abundance of each target was 
normalized to that of 28S rRNA. 
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Luciferase Reporter-based Minigenome Replication Assay of IAV RNA Synthesis 
 
Luciferase reporter-based minigenome replication assay for monitoring IAV 
transcription and replication was performed as previously described (42,53,54). In brief, 
HEK293-FIT-T56-WT or -Mut cells cultured in the presence or absence of tet (to induce 
or repress HA-T56 WT/Mut expression, respectively) were co-transfected using 
Lipofectamine 3000 (Invitrogen) with polymerase II-driven pHW plasmids expressing 
RNP complex genes (PB2, PB1, PA and NP) of influenza A/PR/8/34 virus, and a 
polymerase I-driven luciferase reporter plasmid pHY-Luci (42). Also co-transfected was 
a CMV promoter-driven plasmid expressing the Renilla luciferase (pRL-CMV, 
Promega), which served as an internal control for normalization of transfection 
efficiency. At the indicated time points post transfection, cells were lysed and processed 
for dual-luciferase assay. 
 
 
Immunoblotting, Immunofluorescence Staining, and Confocal Microscopy 
 
Cell lysates were prepared in RIPA buffer and subjected to SDS-PAGE and 
immunoblot analysis as previously described (34,50). Immunofluorescence staining and 
confocal microscopy were performed as previously described (34,50). The following 
monoclonal (mAb) and polyclonal antibodies (pAb) were utilized: rabbit anti-YFV NS3 
pAb (a gift from Charles Rice), which we found to cross-react with DENV2 NS3; mouse 
anti-DENV mAb D1-11(3) (Genetex); mouse anti-DENV prM (clone 2H2) hybridoma 
culture supernatant; goat anti-DENV (BEI Resources), which we found to recognize 
predominantly prM; anti-EMCV 3D pol mAb (a gift from Ann Palmenberg); mouse anti-
HCoV-OC43 N mAb (Millipore); mouse anti-influenza A/WSN/33 (H1N1) NP 5/1 mAb 
(confirmed to react with the NP of A/PR/8/34 virus) and goat anti matrix (M) protein 
antiserum (gifts from Richard Webby); goat anti-influenza B/Hong Kong/8/73 HA pAb 
(BEI Resources NR-3165), which also reacts with the HA of B/Florida/4/06 virus; rabbit 
anti-SeV pAb (a gift from Ilkka Julkumen); rabbit anti-hMPV pAb (45); rabbit anti-
TRIM56 pAb; rabbit anti-TRIF pAb; mouse anti-HA tag mAb (Invivogen), which I have 
confirmed not to react with the HA of either A/PR/8/34 or B/Florida/4/06 virus; mouse 
anti-HA tag mAb (clone 12CA5, Roche); mouse anti-V5 tag mAb (Invivogen); mouse 
anti-Flag M2 mAb (Sigma); mouse anti-actin mAb (Sigma); rabbit anti-β tubulin pAb 
(Santa Cruz); peroxidase-conjugated secondary goat anti-rabbit, goat anti-mouse and 
rabbit anti-goat pAbs; FITC-conjugated secondary goat anti-mouse pAb (Southern 
Biotech); and Alexa Fluor 594-conjugated secondary donkey anti-mouse and chicken 
anti-goat pAbs (Invitrogen). Densitometry quantification of protein bands of interest was 
performed using the Image J software (NIH). 
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Reporter Gene Assay 
 
IFN-β, IL-29 and PRDII promoter activities in transfected cells after different 
treatments were measured using a luc reporter assay as described (39,50). 
 
 
Statistical Analysis 
 
Statistical differences were analyzed using students’ t-test with the SPSS 11.5 
software where appropriate. All P values were two-tailed and P < 0.05 was regarded to 
be statistically significant. Error bars represent standard deviations. 
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CHAPTER 3.    OVERLAPPING AND DISTINCT MOLECULAR 
DETERMINANTS DICTATING THE ANTIVIRAL ACTIVITIES OF TRIM56 
AGAINST FLAVIVIRUSES AND CORONAVIRUS1 
 
 
Introduction 
 
 The innate immune system represents a primary and fundamental component of host 
defense in the immediate-early phase of microbial infections. It is equipped with multi-
layered mechanisms. As sentinels to alert cells to the presence of invading viral 
pathogens, pattern recognition receptors (PRRs) such as the toll-like receptors (TLRs) 
and retinoic-inducible gene-I (RIG-I)-like receptors sense viral nucleic acids, a major 
class of viral pathogen-associated molecular pattern, activating intracellular signaling 
pathways that culminate in production of interferons (IFNs). These antiviral cytokines act 
in a paracrine/autocrine fashion to induce the expression of hundreds of interferon-
stimulated genes (ISGs) that collectively establish an antiviral state, reining in viral 
replication and spread (1-4). In addition to the IFN system, mammalian hosts encode a 
number of intracellular restriction factors that have direct antiviral roles (5). Although 
most of these factors are constitutively expressed at variable levels, many are, not 
surprisingly, also shown to be IFN-inducible. Of these, members of the tripartite motif-
containing (TRIM) protein family are increasingly recognized as active players in 
antiviral innate immunity (28-30). 
 
The TRIM protein family comprises more than 70 members whose functions span a 
broad array of physiological processes, including cell proliferation, differentiation, and 
development, etc (28,31). Structurally, TRIM family members have highly conserved 
arrangement of N-terminal tripartite motifs, i.e., RING, one or two B-boxes, and coiled-
coil domains, and variable C-terminal region that has or has not up to four known 
functional domains (for example, the PRY-SPRY motifs). In general, RING domains 
confer TRIM proteins with E3 ubiquitin (Ub) ligase activity and the ability to recognize 
E2 conjugating enzyme. B-box domains are considered as zinc-binding motifs important 
for protein-protein interactions while coiled-coil domains facilitate self-association, 
turning oligomerized TRIM family proteins into a scaffold for assembling multi-protein 
complexes. In contrast, the C-terminal half of the TRIM family proteins have been 
proposed to be involved in protein-protein interactions, for example, presenting the 
substrate to an E2 conjugating enzyme. Based on the variability in C-terminal domain 
composition, TRIMs can be classified into up to 11 subfamilies (C-I to C-XI), with nine 
TRIM family members that lack a known C-terminal domain setting up subfamily C-V 
(30,31). 
 
___________________________ 
 
1Adapted with permission. Liu B, Li NL, Wang J, Shi PY, Wang T, Miller MA, Li K. 
2014. Overlapping and distinct molecular determinants dictating the antiviral activities of 
TRIM56 against flaviviruses and coronavirus. J Virol 88:13821-13835. 
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As exemplified by TRIM5?, the first and most characterized role in antiviral 
immunity of TRIMs is their ability to act as retroviral restriction host factors (28,29,32). 
In recent years, however, a small number of TRIMs have been appreciated for novel roles 
in modulating antiviral innate immune signaling and in possessing direct antiviral 
activities against viruses of other families (29-31). Of a handful of TRIMs falling into the 
latter group, TRIM79α, a rodent-specific TRIM, restricts tick-borne encephalitis virus 
(TBEV), a classical flavivirus, by targeting the nonstructural (NS)-5 protein for 
lysosome-dependent degradation (55). TRIM56, a C-V subfamily member, is a virus- and 
IFN-inducible factor possessing antiviral activity against bovine viral diarrhea virus 
(BVDV) (34), a ruminant pestivirus classified within the family Flaviviridae shared by 
TBEV. Although the precise mechanism of action remains elusive, the antiviral effect is 
abolished by mutations that abrogate the E3 Ub ligase activity or by deletions within the 
last ~130 amino acids (aa) of the C-terminus, suggesting the importance of the RING 
domain-residing E3 ligase activity and C-terminal integrity in TRIM56’s anti-BVDV 
actions. However, it is unknown whether the B-box or coiled-coil domains or other parts 
of the C-terminal region also play a part in the antiviral barrier function of TRIM56. Also 
left unanswered is the question of the specificity and spectrum of TRIM56’s antiviral 
actions. Of particular interest, whether TRIM56 impacts medically important RNA 
viruses has not been determined. 
 
 This study is the first to demonstrate that human TRIM56 possesses antiviral activity 
against yellow fever virus (YFV) and dengue virus (DENV), two classical flaviviruses 
that are threatening the well-beings of approximately half of the world’s population (56). 
Additionally, I report that TRIM56 restricts a human coronavirus, HCoV-OC43, which is 
responsible for a significant share of common cold cases. In contrast, I find that TRIM56 
does not impact propagation of encephalomyocarditis virus (EMCV), a picornavirus, 
suggesting TRIM56 does not act on positive-strand RNA viruses indiscriminately. By 
extensive domain mapping, I discovered that distinct molecular determinants underpin 
the observed antiviral effects against different viral families. Consistent with this, I found 
that while TRIM56 inhibits flavivirus RNA replication, it acts at the stage of coronavirus 
packaging/release. These data delineate the antiviral spectrum of TRIM56 against 
positive-strand RNA viruses and shed novel light on the molecular basis of the versatility 
and specificity, and the mechanisms of action of this host restriction factor against 
medically-important RNA viruses. 
 
 
Results 
 
 
Ectopic Expression of TRIM56 Inhibits Propagation of YFV, DENV2 and HCoV-
OC43, but Not That of EMCV 
 
We have previously reported that both human and bovine TRIM56 restrict the 
replication of BVDV, a ruminant pestivirus in the family Flaviviridae, but have no 
demonstrable effect on vesicular stomatitis virus (VSV), a rhabdovirus (34). To 
understand the specificity and spectrum of the antiviral activity of TRIM56 against 
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positive-strand RNA viruses, I determined the impact of human TRIM56 overexpression 
on multiplication of four RNA viruses of three distinct viral families. These included two 
medically-important flaviviruses, YFV and DENV2; a human coronavirus, HCoV-OC43; 
and a picornavirus, EMCV. 
 
To gauge the effect of TRIM56 without the confounding factor of clonal variation, I 
established HEK293 cells with conditional expression of N-terminal HA-tagged TRIM56 
using the FIT expression system. This strategy was chosen since it enables the 
development of isogenic, stable cell lines harboring tet-inducible expression of a protein 
of interest from a specific genomic location. The resultant cell line, designated as 293-
FIT-T56, exhibited no detectable HA-TRIM56 protein when cultured in the absence of 
tet (-tet) but demonstrated robust HA-TRIM56 expression upon tet addition to culture 
medium (+tet) (Figure 3-1A, left panel, compare lane 1 vs 2). When infected with YFV-
17D at an MOI of 0.1, cells without HA-TRIM56 expression (-tet) harbored high levels 
of viral NS3 antigen at 24 hours post-infection (hpi) (lane 3). In contrast, in cells induced 
for HA-TRIM56 expression (+tet) NS3 expression was abrogated (lane 4). In agreement 
with this, there was an 8-fold reduction (P < 0.05) in progeny virus titers in supernatants 
of 293-FIT-T56 cells cultured in the presence of tet as compared with those in the 
absence of tet (Figure 3-1A, right panel). Similar results were obtained in HeLa cells 
with tet-inducible expression of HA-TRIM56, i.e., HeLa-FitA2-T56 (Figure 3-1B), 
confirming that the finding is not a cell type-specific phenomenon. We also observed that 
stable, constitutive expression of C-terminal Flag-tagged TRIM56 (TRIM56-Flag) in 
HEK293 cells via retroviral gene transfer (i.e., 293-T56 cells), blunted YFV-17D NS3 
protein expression and progeny virus production over a 3-day observation period as 
compared to control HEK293 cells (data not shown). Thus, the anti-YFV activity was 
also reproduced when ectopic expression of TRIM56 was achieved using a different 
expression system.   
 
I next examined how TRIM56 overexpression affected propagation of DENV2, a 
flavivirus closely related to YFV. As in the case of YFV-17D, replication of the 16681 
strain of DENV2 was crippled in 293-FIT-T56 cells upon turning on HA-TRIM56 
expression, as revealed by diminished expression of viral E protein (Figure 3-1C, left 
panel, lane 3 vs 4) and an approximately 1-log decrease (P < 0.05) in infectious virus 
production (right panel). Moreover, substantial reduction in prM protein abundance was 
observed in HeLa-FitA2-T56 cells infected with DENV2 when HA-TRIM56 expression 
was induced by addition of tet (Figure 3-1D, compare lanes 4 vs 3), corroborating 
TRIM56-mediated inhibition of DENV2 infection in another cell line.  
 
Since TRIM56 is most abundantly expressed in the lungs (34), I reasoned that 
TRIM56 might contribute to cellular defense against respiratory viruses. I thus 
investigated whether manipulation of TRIM56 abundance alters cellular permissiveness 
for HCoV-OC43, a human coronavirus that typically causes common cold. Indeed, an 
antiviral effect of TRIM56 was observed in 293-FIT-T56 cells infected with HCoV-
OC43, with cells induced for HA-TRIM56 expression exhibiting substantially lower viral 
N protein abundance and producing 1-log (P < 0.05) fewer infectious viruses in culture 
medium than cells not induced (Figure 3-1E). 
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Figure 3-1. Ectopic expression of TRIM56 inhibits multiplication of YFV, DENV2 
and HCoV-OC43, but not that of EMCV. 
(A) Left: Immunoblot analysis of the expression of N-terminal HA-tagged TRIM56 
(using anti-HA antibody) and YFV NS3 in 293-FIT-T56 with or without tetracycline (tet) 
and mock infected or infected with YFV-17D for 24 h (MOI = 0.1). Right: Progeny virus 
production was determined by TCID50 assay in culture supernatants of 293-FIT-T56 cells 
with or without tet treatment at 24 hours post-infection (hpi) with YFV-17D (MOI = 0.1). 
Asterisk (*) denotes that statistical differences exist between -tet and +tet cells with a P 
value of < 0.05. (B) HeLa-FitA2-T56 cells inhibited NS3 protein expression at 72 hpi of 
YFV-17D (MOI = 0.5). (C, E and F) Left panels: Immunoblot analysis of of HA-
TRIM56 and viral protein expression in mock- or viruses-infected 293-FIT-T56 cells 
with or without tet treatment. Right panels: progeny viral titers for the infected cells in 
the absence or presence of tet treatment, under similar experimental settings of (A) except 
that the cells were infected with DENV2-16681 strain (MOI = 0.1) for 24 h for 
immunoblot analysis and 72 h for TCID50 assay in (C), with HCoV-OC43 (MOI = 0.1) 
for 24 h in (E), or with EMCV (MOI = 0.01)  for 18 h in (F), respectively. The viral 
protein antibodies used for immunoblotting included anti-DENV2 envelope (E) in (C), 
anti-HCoV-OC43 nucleocapsid (N) protein in (E), and anti-EMCV 3D polymerase (pol) 
in (F). (D) Tet-inducible expression of HA-TRIM56 in HeLa-FitA2-T56 cells inhibited 
prM protein expression at 36 hpi of DENV2 (MOI = 0.1). 
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Given that all positive-strand RNA viruses replicate on cytoplasmic membranes (57) 
and that TRIM56 exhibits a cytoplasmic distribution, I wondered whether TRIM56 also 
inhibits other positive-strand RNA viruses. I thus examined the effect of conditional 
expression of HA-TRIM56 on propagation of EMCV, a prototype member of the family 
Picornaviridae. Western blotting revealed 293-FIT-T56 cells with or without HA-
TRIM56 induction supported comparable production of 3D polymerase protein, the 
replicase core of EMCV, following infection with the virus (MOI = 0.01) (Figure 3-1F, 
left panel). In line with this, there was no appreciable difference in progeny virus yields 
in culture supernatants between tet-treated and tet-untreated cells (Figure 3-1F, right 
panel). These data reveal that although ectopic expression of TRIM56 impedes the 
multiplication of flaviviruses (YFV and DENV2) and HCoV-OC43, it does not target 
positive-strand RNA viruses indiscriminately, since TRIM56 has no demonstrable 
antiviral activity against EMCV.  
 
In aggregate, the aforementioned experiments delineate the antiviral spectrum of 
TRIM56 against positive-strand RNA viruses and reveal that when ectopically expressed, 
this TRIM protein acts to curb infections by flaviviruses (YFV and DENV2) and HCoV-
OC43. 
 
 
TRIM56 Expressed at Physiologic Levels Restricts Infections by YFV, DENV2 and 
HCoV-OC43 
  
Next, I determined whether TRIM56 expressed at physiologic levels poses a barrier 
to infection with the three RNA viruses identified above. To achieve this goal, I stably 
knocked down endogenous TRIM56 and measured the impact on viral protein expression 
and progeny virus production. Compared with that in HeLa cells bearing a non-targeting, 
scrambled control (Ctrl) shRNA, TRIM56 protein abundance in pools of HeLa cells 
stably transduced with a TRIM56 shRNA (HeLa-shT56-094 cells) was reduced by ~80% 
(Figure 3-2A, left panel). When infected with YFV-17D, HeLa-shT56-094 cells had 
markedly elevated NS3 protein levels and a >1-log increase (P < 0.05) in progeny virus 
yields as compared with HeLa-Ctrl cells (Figure 3-2A). Moreover, the enhanced YFV 
replication in TRIM56 knockdown cells was confirmed by immunostaining of YFV NS3 
expression (data not shown). TRIM56 depletion also rendered cells more permissive to 
DENV2. As shown in Figure 3-2B, following DENV2 infection, we observed elevated 
DENV NS3 expression (immunoblotting data in left panel), increased progeny virus 
yields (middle panel) and higher percentage of cells with discernable prM expression 
(right panel) in TRIM56 knockdown cells compared with the control cells. Thus, the 
effects of TRIM56 depletion on DENV mirrored with those seen in YFV-17D-infected 
cells. The same can be said concerning the impact of TRIM56 silencing on HCoV-OC43 
infection; we found that HeLa-shT56-094 cells supported higher levels of viral N protein 
expression and produced 6-fold more (P < 0.01) progeny viruses than HeLa-Ctrl cells 
(Figure 3-2C). Collectively, the TRIM56 knockdown experiments corroborate the 
physiologic relevance of the finding that TRIM56 is an intrinsic host restriction factor of 
YFV, DENV2 and HCoV-OC43. 
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Figure 3-2. The endogenous TRIM56 protein restricts propagation of YFV, 
DENV2 and HCoV-OC43.  
(A) Left panel: Immunoblot analysis of the expression of TRIM56 (using anti-TRIM56 
antibody) and YFV NS3 (using anti-YFV NS3 antibody) in HeLa cells stably transduced 
with either a non-targeting, scrambled control shRNA (Ctrl) or TRIM56 shRNA-094 
(shT56) at 72 hpi with YFV-17D (MOI = 0.5). Actin served as a loading control to 
demonstrate equal sample loading. Right panel: Culture supernatants of virus-infected 
cells were harvested at 36 hpi and subjected to TCID50 assay for determination of 
progeny virus production. (B) Left panel: Immunoblot analysis of TRIM56 and DENV2 
NS3 (using anti-YFV NS3) expression in HeLa-Ctrl and HeLa-shT56-094 cells at 60 hpi 
with DENV2-16681 (MOI = 1.5). Middle panel: Progeny virus titers in culture 
supernatants of the DENV2-infected cells (MOI = 0.5, 60 hpi). Note that HeLa-Ctrl cells 
produced 12-fold fewer progeny viruses than HeLa-shT56-094 cells. Right panel: 
Immunostaining of DENV2 prM expression (using DENV 2H2 hybridoma supernatant) 
in HeLa-Ctrl and HeLa-shT56-094 cells at 60 hpi with DENV2-16681 strain (MOI = 
0.5). The mean percentage of cells with discernable prM expression was quantified from 
three independent images and shown at the lower left corner of each prM panel. (C) Left 
panel: Immunoblot analysis of TRIM56 and N protein (N) (using anti-HcoV OC43 N) 
expression in HeLa-Ctrl and HeLa-shT56-094 cells at 48 hpi with HCoV-OC43 (MOI = 
0.01). Right panel: Progeny virus titers in culture supernatants of the virus-infected cells. 
“*”and “**” indicate that statistical differences exist between Ctrl and shT56 cells with a 
P value of < 0.05 and < 0.01, respectively. 
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The Antiviral Effects of TRIM56 Are Not Attributed to General Augmentation of 
IFN Response or to Regulation of Cell Growth 
 
TRIM56 possesses the ability to promote type I IFN response induced via the TLR3 
signaling pathway (39). In light of this, I studied whether heightened induction of the IFN 
antiviral response is responsible for the retarded viral propagation in TRIM56-expressing 
cells. To this end, I examined induction of ISG15 and/or ISG56, well-characterized 
sensitive markers of the IFN response, in cells with or without TRIM56 expression and 
infected with YFV and HCoV-OC43, respectively. As shown in Figure 3-3A, there was 
no detectable ISG15 protein in control HEK293 or 293-T56 cells infected with YFV-
17D, although robust induction of ISG15 was observed in these cells following Sendai 
virus infection. Thus, regardless of the status of TRIM56 expression, there is no 
discernable IFN response when infected with YFV. Likewise, expression of ISG15 or 
ISG56 was undetectable in 293-FIT-T56 with or without HA-TRIM56 induction, and 
prior to and after HCoV-OC43 infection (Figure 3-3B), despite that there was a 
substantial decline in N protein abundance in these cells upon turning on HA-TRIM56 
expression (lanes 4 vs 3, Figure 3-3B). Consistent with these data, there was no 
significant up-regulation of transcription for ISG56, IFN-β, or IL-29, in 293-FIT-T56 
cells with (+tet) or without (-tet) HA-TRIM56 induction when infected with YFV, 
DENV2 or HCoV-OC43 (data not shown). I conclude from these data that general 
augmentation of the IFN antiviral response is not responsible for the antiviral effects of 
TRIM56 against flaviviruses and HCoV-OC43.  
 
I also considered the possibility that TRIM56 may impact cell growth, producing a 
condition unfavorable for viral propagation. However, I did not find any difference in cell 
proliferation between 293-FIT-T56 cells induced and repressed for HA-TRIM56 
expression over a seven-day observation period (Figure 3-3C), nor did I observe obvious 
cell death or apoptosis before and following tet-induction of HA-TRIM56 (data not 
shown). 
 
 
TRIM56’s Antiviral Actions Do Not Depend upon TLR3/TRIF, RIG-I or STING  
 
TRIM56 has been reported to form a complex with TRIF and STING, thereby 
potentiating TLR3 and STING-dependent antiviral signaling pathways, respectively 
(39,58). Although I did not find heightened IFN or ISG induction to be responsible for 
TRIM56’s antiviral activities, the possibility could not be ruled out that IFN-independent 
mechanisms through the TLR3/TRIF-, RIG-I-, or STING-axis may contribute. To clarify 
this, I determined whether knockdown of TRIF, RIG-I or STING alters the antiviral 
activities of TRIM56 against YFV and HCoV-OC43. HEK293-derived cells generally 
have very low expression of TLR3, and I found this to be the case with the 293-FIT cells 
(data not shown). In line with this, there was little induction of ISG56 transcript in 
extracellular poly-I:C-stimulated cells without HA-TRIM56 induction (Figure 3-4A, -
tet). Turning on HA-TRIM56 expression (+tet) strongly augmented induction of ISG56 
by poly-I:C, but this response was curtailed upon TRIF silencing (Figure 3-4A). This is 
consistent with our previous report that TRIM56 positively regulates TLR3 
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Figure 3-3. The antiviral effects of TRIM56 do not result from up-regulation of 
IFN response or from modulation of cell growth.  
(A) Immunoblot analysis of ISG15 protein abundance in 293 cells or cells stably 
overexpressing TRIM56-Flag (293-T56) at 24 hpi with YFV-17D (MOI = 0.1) or at 12 
hpi with Sendai virus (SeV) as a positive control for induction of the IFN response. (B) 
Immunoblot analysis of HA-TRIM56, HCoV-OC43 N protein, ISG15, and ISG56 
expression in 293-FIT-T56 cells that were mock infected or infected with HCoV-OC43 
(MOI = 0.1) for 24 h in the absence (odd numbered lanes) or presence (even numbered 
lanes) of tet treatment. Asterisk indicates a nonspecific band detected by the anti-ISG56 
antibody. (C) Growth curves of 293-FIT-T56 cells cultured with or without tet was 
assessed by cell number counts over a 7-day observation period. 
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Figure 3-4. TRIM56’s antiviral actions are independent of TRIF, RIG-I and 
STING.  
HEK293-FIT-T56 cells cultured without (-tet) or with tet (+tet) were transfected with a 
negative control siRNA (si-ctrl) or siRNA targeting TRIF or RIG-I, or shRNA targeting 
STING (shSTING) or its control vector (Ctrl). At 48 h post transfection, the cells were 
mock-treated, infected with YFV-17D or HCoV-OC43 for 24 h (MOI = 0.1), or treated 
with poly-I:C (pIC) or Sendai virus (SeV) for 10 h. qPCR was performed with total 
cellular RNA to measure abundance of TRIF and ISG56 mRNAs before or after pIC 
treatment in (A), or that of RIG-I and ISG56 mRNAs before and following SeV infection 
in (B).  (C) Progeny virus production was determined in cell-free supernatants following 
silencing TRIF or RIG-I and infection of YFV-17D (left) or HCoV-OC43 (right). (D) 
Left panel shows qRT-PCR analysis of the abundance of STING transcript after 
transfection of control vector or shSTING. Progeny virus production was determined in 
cell-free supernatants following transfection of control vector or shSTING and infection 
with YFV-17D (middle) or HCoV-OC43 (right). “*” and “**” denote that statistical 
differences exist between -tet and +tet cells (C and D), or between ctrl and knockdown 
cells (A and B) with a P value of < 0.05 and < 0.01, respectively. 
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signaling by interacting with TRIF (39). Also in agreement with our previous finding that 
TRIM56 has no appreciable role in RIG-I signaling (39), tet-induction of HA-TRIM56 
had no effect on upregulation of ISG56 mRNA by Sendai virus infection, which was 
blunted by RIG-I siRNA (Figure 3-4B). Despite efficient knockdown of TRIF or RIG-I, 
TRIM56’s antiviral activities against YFV and HCoV-OC43 remained unchanged 
(Figure 3-4C). I also did not find knockdown of STING alters TRIM56’s suppressive 
effects on YFV or HCoV-OC43 multiplication (Figure 3-4D).  
 
 
Development of HEK293 Cells with Conditional Expression of Various TRIM56 
Mutants for Mapping of the Antiviral Determinants 
 
In order to dissect the mechanisms by which TRIM56 exerts its antiviral actions 
against different RNA viruses, it was necessary to define the domains/activities critical 
for TRIM56’s restriction of each virus. Thus, I established HEK293 cell lines with tet-
inducible expression of a series of HA-TRIM56 mutants using the strategy we adopted to 
generate the 293-FIT-T56 cell line. These included the E3 Ub ligase-deficient 
CC21/24AA mutant (referred to as CC21/24AA), mutants lacking the RING (referred to 
as ΔRING), B-box (referred to as ΔB-box) or coiled-coil (referred to as ΔCoiled-coil) 
domains, respectively, and mutants bearing deletions in the C-terminal portion – Δ355-
433 (lacking aa 355-433), Δ621-695 (lacking aa 621-695), and Δ693-750 (lacking aa 
693-750). As shown in Figure 3-5, there was negligible expression of WT and mutant 
HA-TRIM56 when these cell lines were cultured in tet-free medium (odd-numbered lanes 
except lane 17), while robust expression of HA-TRIM56 and its mutants (even-numbered 
lanes) with comparable levels and expected molecular masses was induced upon tet 
addition.  
 
 
The E3 Ligase Activity and the Integrity of the C-terminus of TRIM56 Are Critical 
for the Antiviral Activity against YFV and DENV2, while the B-box Is Dispensable 
 
Having created HEK293 cell lines with tet-regulated expression of various TRIM56 
mutants, I used them in conjunction with the WT TRIM56-inducible 293-FIT-T56 cells 
to map the molecular determinants dictating TRIM56’s antiviral activities against the 
three RNA viruses. First, I examined how YFV-17D replication differed among these cell 
lines. As shown in Figure 3-6A, tet induction of the ΔB-box mutant blunted YFV NS3 
protein abundance (compare lanes 12 vs 11) in infected cells, acting with similar potency 
to that of WT TRIM56 (compare lanes 4 vs 3). In stark contrast, this inhibitory effect was 
absent when comparing cells expressing ΔRING, Δ355-433, Δ621-695 and Δ693-750 
mutants with cells not induced to express (for ΔRING mutant, compare lanes 24 vs 23; 
for Δ355-433 mutant, compare lanes 20 vs 19; for Δ621-695 mutant, compare lanes 28 vs 
27; and for Δ693-750 mutant, compare lanes 32 vs 31). These data imply that the RING 
domain and the integrity of the C-terminal parts are critical for the antiviral function of 
TRIM56 against YFV, while the B-box is dispensable. To determine the involvement of 
the E3 ligase activity, which lies in the RING-domain, I subjected the CC21/24AA 
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Figure 3-5. Characterization of HEK293 cells that conditionally express 
individual TRIM56 mutants in a tet-inducible manner. 
Upper panel: Schematic representation of TRIM56 protein domains and the individual 
TRIM56 mutants investigated in this study. Lower panel: Immunoblot analysis of HA-
TRIM56 and actin expression in 293-FIT-T56 and the indicated 293-FIT-T56 Mut cells 
with or without tet treatment for 48 h. 
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Figure 3-6. The E3 ligase activity and the integrity of the C-terminal parts of 
TRIM56 are essential for the antiviral activity against YFV. 
(A) Immunoblot analysis of HA-tagged wild-type and mutant TRIM56 and YFV NS3 
protein expression in 293-FIT-T56 WT/Mut cells in the absence (odd numbered lanes) or 
presence (even numbered lanes) of tet, and mock-infected or infected with YFV-17D for 
24 h (MOI = 0.1). There were eight lines of 293-FIT-T56 WT/Mut cells examined in 
total, data from which are shown in eight blocks of immunoblot collections. (B) Progeny 
virus production in culture supernatants of 293-FIT-T56 WT/Mut cells cultured in the 
absence or presence of tet at 24 hpi with YFV-17D (MOI = 0.1). 
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mutant inducible cells to YFV-17D infection. Tet induction of CC21/24AA mutant had 
no effect on YFV NS3 expression (compare lanes 8 vs 7), indicating that the E3 ligase 
activity plays a critical role in conferring the anti-YFV activity. This notion was 
additionally supported by data obtained from YFV-17D-infected 293-T56 and 293-T56-
CC21/24AA cells in which TRIM56-Flag or its CC21/24AA mutant version was 
expressed in a constitutive fashion (data not shown).  
 
Consistent with the immunoblot results, there was a 10-13-fold decrease in progeny 
virus production in 293-FIT-T56 and 293-FIT-T56-ΔB-box cells in the induced state 
compared with cells cultured in the absence of tet. However, the decline in progeny viral 
yield upon tet induction was not seen in 293-FIT-T56-CC21/24AA, -ΔRING, -Δ355-433, 
-Δ621-695 or -Δ693-750 mutant cells (Figure 3-6B). Notably, an intermediate antiviral 
phenotype was observed upon inducible expression of ΔCoiled-coil. While this mutant 
retained the ability to inhibit YFV-17D, it was less effective than WT TRIM56 or the 
ΔB-box mutant, as determined by immunoblotting of NS3 (Figure 3-6A, compare lanes 
16 vs 15) and measurement of progeny virus production (Figure 3-6B). Thus, the coiled-
coil domain is, to some extent, involved in the restriction of YFV by TRIM56, although 
the part this domain plays is not as crucial as those played by the E3 ligase activity and 
the C-terminal portions of the protein. 
 
Next, I analyzed the molecular determinants that control the TRIM56 restriction of 
DENV2 using 293-FIT-T56 cells and our panel of mutant TRIM56 inducible cell lines. 
The TRIM56 domain involvement profile uncovered (Figure 3-7) was almost identical to 
that required for the anti-YFV action. Yet, there was one exception – the ΔCoiled-coil 
mutant still effectively inhibited the accumulation of DENV2 prM protein (Figure 3-7A, 
compare lanes 16 vs 15) and progeny virus production (Figure 3-7B), similar to those 
seen with WT TRIM56 or ΔB-box (Figure 3-7A-B), suggesting that unlike the case of 
YFV, the anti-DENV2 action is not strictly dependent on TRIM56’s coiled-coil domain. 
 
 
The Functional TRIM56 Mutants Exert Their Antiviral Effects Independent of the 
Endogenous, WT TRIM56 Protein 
 
I recognize one caveat concerning the experiments probing the antiviral functions of 
the TRIM56 mutants. One cannot exclude the possibility that some of the mutants 
functioned by pairing with the endogenous WT TRIM56 protein, despite their expression 
levels in ectopic expression settings were ~12 fold higher than the latter (Figure 3-8B). 
However, this scenario is unlikely. The coiled-coil domain that is responsible for 
facilitating dimerization or oligomerization of TRIMs is dispensable for the antiviral 
activities of TRIM56 against DENV2 (Figure 3-7B) and HCoV-OC43 (Figure 3-9B, see 
the next section), except in the case of YFV (Figure 3-6B) it contributed to a minor 
extent. To confirm this notion, I conducted siRNA knockdown experiments to efficiently 
silence the endogenous TRIM56 mRNA (Figure 3-8A) without affecting the 
exogenously introduced mutant TRIM56 expression (Figure 3-8B), using an siRNA 
specifically targeting the 3’UTR region of the human TRIM56 transcript. As shown in 
Figure 3-8C, knockdown of endogenous WT TRIM56 by this siRNA did not reverse the 
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Figure 3-7. The suppression of DENV2 multiplication by TRIM56 requires its E3 
ligase activity and the integrity of the C-terminal portions. 
(A) Immunoblot analysis of HA-TRIM56 (WT or mut) and DENV2 prM protein 
abundance (using goat anti-DENV2 antibody) in 293-FIT-T56 WT or individual Mut 
cells in the absence (odd numbered lanes) or presence (even numbered lanes) of tet, and 
mock-infected or infected with DENV2-16681 strain (MOI = 1) for 60 h. (B) Progeny 
virus production in culture supernatants of 293-FIT-T56 WT/Mut cells cultured in the 
absence or presence of tet at 60 hpi with DENV2-16681 strain (MOI = 1). “*” and “***” 
indicate that statistical differences exist between -tet and +tet cells with a P value of < 
0.05 and < 0.001, respectively. 
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Figure 3-8. Knockdown of endogenous TRIM56 via an siRNA targeting the 3’ 
UTR of human TRIM56 transcript does not affect the antiviral activities of the 
ectopically expressed WT TRIM56 or functional TRIM56 mutants. 
qRT-PCR was performed to measure the abundance of endogenous TRIM56 transcript 
(panel A, using primers amplifying the 3’ UTR of TRIM56 mRNA), total TRIM56 
transcript including the endogenous and exogenously overexpressed TRIM56 mRNAs 
(panel B, using primers amplifying the coding region of TRIM56 mRNA), and 
intracellular YFV RNA (panel C, using primers amplifying the NS2B region of YFV 
RNA) in 293-FIT-T56 (WT), 293-FIT-T56-?Coiled-coil and 293-FIT-T56-?B-box cells 
cultured with or without tet, and transfected with a negative control siRNA (Ctrl) or 
siRNA targeting 3’ UTR of TRIM56 (siT56). Cell were either mock-infected or infected 
with YFV-17D for 24 h (MOI = 1). Note that the TRIM56-3’UTR siRNA only knocked 
down endogenous TRIM56 transcript but not the exogenously introduced (tet-inducible) 
WT or mutant TRIM56 which expressed only the coding region of the gene. (panel B); 3) 
the ?Coiled-coil mutant inhibited YFV RNA replication less efficiently than WT 
TRIM56 or the ?B-box mutant; and 4) the TRIM56-3’UTR siRNA had no demonstrable 
effects on the antiviral activity of any of the exogenously expressed TRIM56 forms. “*” 
and “**” denote that statistical differences exist between -tet and +tet cells (panel C), or 
between control and knockdown cells (panel A) with a P value of < 0.05 and < 0.01, 
respectively. “◊” denotes a P value of 0.05-0.06. 
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significant dip in intracellular YFV RNA levels in 293-FIT-T56-ΔB-box or 293-FIT-
T56-ΔCoiled-coil cells imposed by tet-induction of mutant TRIM56, suggesting that the 
antiviral effects of these mutants are not dependent upon the endogenous WT protein. 
 
 
TRIM56’s Suppression of HCoV-OC43 Multiplication Depends on Its E3 Ligase 
Activity, but Not the Integrity of the C-terminus or B-box or Coiled-coil Domains 
 
To determine whether the findings with TRIM56 domain/activity requirements for its 
restriction of flaviviruses can be extended to HCoV-OC43, I compared the HEK293 tet-
inducible cell lines expressing WT or various TRIM56 mutants for their ability to support 
HCoV-OC43 infection. I monitored expression of the viral structural N protein in cell 
lysates by western blotting (Figure 3-9A) and progeny viral titers in culture supernatants 
via TCID50 assay (Figure 3-9B). When infected with HCoV-OC43 at an MOI of 0.1, 
abundant expression of N protein was detected in all cell lines that were cultured in tet-
free medium at 24 hpi. However, upon induction of WT TRIM56 or mutants lacking B-
box or the coiled-coil domain, or any of the C-terminal deletion mutants (Δ355-433, 
Δ621-695 and Δ693-750) by tet, N protein abundance was compromised (Figure 3-9A). 
In contrast, there was no reduction in the expression level of this viral protein when the 
tet-treated cells started to express the CC21/24AA or ΔRING mutants, both of which are 
defective for E3 ligase activity (Figure 3-9A, compare lanes 8 vs 7 and lanes 24 vs 23, 
respectively). Analysis of progeny virus production confirmed that all TRIM56 mutants 
but CC21/24AA and ΔRING retained the ability to curtail HCoV-OC43 propagation 
(Figure 3-9B). Taken together, these observations demonstrate that the E3 ligase activity 
alone, and not other domains/portions of TRIM56, mediates the anti-HCoV-OC43effect. 
 
 
TRIM56 Inhibits YFV/DENV2 Propagation by Impairing Intracellular Viral RNA 
Replication, whereas It Curbs HCoV-OC43 Spread by Targeting a Later Step in the 
Viral Life Cycle  
 
Because TRIM56’s antiviral effects against flaviviruses and HCoV-OC43 share a 
dependence on the E3 ligase activity but differ in the requirement of the C-terminal 
regions, I wondered to what extent their mechanisms of actions overlapped. Thus, I 
determined the effects of TRIM56 overexpression on different stages of YFV-17D (the 
prototype of flaviviruses) and HCoV-OC43 life cycles. Three cell lines were included in 
the analysis: 293-FIT-T56-WT, 293-FIT-T56-CC21/24AA, and 293-FIT-T56-Δ621-695. 
Cells were cultured in the absence or presence of tet to repress or induce TRIM56 (or 
mutant TRIM56) expression, respectively, followed by infection with YFV-17D  
(Figure 3-10A) or HCoV-OC43 (Figure 3-10B) at an MOI of 1. At 1, 12 and 24 hpi, 
after extensive washes to remove extracellular virus and viral RNAs, cells were lysed for 
total RNA extraction, followed by measurement of intracellular viral RNA levels by 
qPCR. Parallel assays of viral titers in culture supernatants at 24 hpi confirmed that 
induction of TRIM56 but not  CC21/24AA or Δ621-695 mutants significantly decreased 
progeny YFV-17D yield, and that expression of WT TRIM56 or Δ621-695 but not 
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Figure 3-9. The inhibition of HCoV-OC43 propagation by TRIM56 is dependent 
upon its E3 ligase activity, but not upon the integrity of the C-terminal portions, or 
the B-box or coiled-coil domains. 
(A) Immunoblot analysis of HA-TRIM56 (WT or mut) and HCoV-OC43 N protein (N) 
abundance in 293-FIT-T56 WT or individual Mut cells in the absence (odd numbered 
lanes) or presence (even numbered lanes) of tet, and mock-infected or infected with 
HCoV-OC43 (MOI = 0.1) for 24 h. (B) Progeny virus production in culture supernatants 
of 293-FIT-T56 WT/Mut cells in the absence or presence of tet at 24 hpi with HCoV-
OC43 (MOI = 0.1).  
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Figure 3-10. TRIM56 blunts YFV and DENV2 infection by targeting intracellular 
viral RNA replication, but inhibits HCoV-OC43 propagation by acting on a later 
step in the viral life cycle. 
(A) qRT-PCR analysis of intracellular YFV RNA abundance in 293-FIT-T56 (WT), -
CC21/24AA or -Δ621-695 cells cultured in the absence or presence of tet, and mock-
infected or infected with YFV-17D (MOI = 1) for 1, 12 and 24 h, respectively. (B) qRT-
PCR analysis of intracellular HCoV-OC43 N RNA abundance in 293-FIT-T56 (WT), -
CC21/24AA or -Δ621-695 cells cultured in the absence or presence of tet, and mock-
infected or infected with HCoV-OC43 (MOI = 1) for 1, 12 and 24 h, respectively. (C) 
293-FIT-T56 cells induced (+tet) or repressed (-tet) for HA-TRIM56 expression were 
transfected with WT or the replication-defective NS4B P104R mutant DENV2-TSV01 
replicon RNA (designated as DEN-Rep-WT or -Mut). At indicated time points post 
transfection, cells were lysed and assayed for Renilla luciferase activity as readout of 
DENV RNA replication. “*” and “***” indicate that statistical differences exist between 
-tet and +tet cells with a P value of < 0.05 and < 0.001, respectively. 
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CC21/24AA led to a significant dip in HCoV-OC43 titers (data not shown). At 1 hpi, 
intracellular viral RNA levels for YFV-17D or HCoV-OC43 were indistinguishable 
between cells cultured without and with tet, regardless of the cell line examined (bearing 
WT or mutant TRIM56), suggesting that TRIM56 does not impede virus-receptor 
interaction or early cellular entry of either virus. 
 
However, as infection progressed a different picture regarding the effects of TRIM56 
emerged between the two viruses. In the case of YFV-17D (Figure 3-10A), intracellular 
viral RNA abundance peaked at 24 hpi, with no significant further increase at 36 hpi 
(data not shown), and was comparable among all three cell lines cultured in tet-free 
medium (without WT or mutant HA-TRIM56 induction). However, the peak level of 
viral RNA in tet-induced 293-FIT-T56 cells was 1 log lower than in uninduced cells, 
proportional to the difference in progeny viral titers. This implies that TRIM56 blunts 
YFV infection by targeting intracellular viral RNA replication. In contrast, 293-FIT-T56-
CC21/24AA and -Δ621-695 cells in induced state harbored more viral RNA than those 
cultured in the absence of tet, a phenomenon more appreciable at 12 than 24 hpi. The 
moderate increase in viral replication in these cells may reflect a dominant-negative 
effect of these TRIM56 mutants on endogenous WT TRIM56. In contrast to what was 
observed with YFV, in cells infected with HCoV-OC43 (Figure 3-10B), copy numbers 
of intracellular viral N RNA reached plateau at 12 hpi, and there was no difference 
among 293-FIT-T56-WT, -CC21/24AA or -Δ621-695 cells irrespective of tet treatment. 
Collectively, the significant decline in progeny HCoV-OC43 titers in 293-FIT-T56-WT 
and -Δ621-695 cells in induced state does not arise from impaired viral entry or RNA 
replication but rather is attributed to effect(s) of the TRIM56 E3 ligase on a later step in 
the viral life cycle, most likely virus packaging and/or egress. 
 
To corroborate that TRIM56 curbs flaviviral RNA replication, I performed transient 
viral RNA replication assay in 293-FIT-T56 cells using WT or a replication-defective 
mutant (NS4B P104R) DENV2 replicon encoding Renilla luciferase.  At 4 h post 
transfection, there was no difference in luciferase activity in cells transfected with either 
WT or mutant replicon, regardless of HA-TRIM56 expression status, suggesting little 
impact of TRIM56 on DENV2 RNA translation (Figure 3-10C). However, different 
replication kinetics of the WT replicon were observed between +tet and -tet cells at later 
time points. Specifically, in cells repressed for HA-TRIM56 expression (-tet), the WT 
DENV2 replicon started to replicate at 24 h post transfection and climbed progressively 
in the next 2 days (48 and 72 h, Figure 3-10C). In stark contrast, in cells with induced 
HA-TRIM56 (+tet), the WT replicon did not replicate in the first 48 h. Although this 
replicon began to replicate at 72 h, its replication level, as gauged by luciferase activity, 
was significantly lower than that in -tet cells. As a negative control, the replication-
deficient NS4B mutant replicon failed to synthesize viral RNAs (41) and displayed a 
continuous decline in luciferase activity, regardless of HA-TRIM56 expression status 
(i.e., -tet or +tet) (Figure 3-10C, dashed lines). These data confirm that TRIM56 acts on 
the viral RNA replication step of DENV2 infection. 
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Discussion 
 
In this study, I have examined the roles of human TRIM56 in acting as an antiviral 
host factor against diverse positive-strand RNA viruses. Our data demonstrate that 
TRIM56 bears antiviral activities against two medically-important flaviviruses (YFV and 
DENV2) and extend the antiviral spectrum of this TRIM to include a human coronavirus 
(HCoV-OC43). Not only did I show that ectopic expression of TRIM56 put a check on 
these viruses (Figure 3-1), but our data obtained from cells depleted for the endogenous 
protein confirmed that physiologic levels of TRIM56 posed an antiviral barrier  
(Figure 3-2). No less important, the effects were reproduced in multiple cell types and 
regardless of the expression system utilized. Of note, preceded by demonstration of an 
inhibitory effect of TRIM56 on a ruminant pathogen, BVDV (34), the novel findings in 
the present study, for the first time, show that human TRIM56 functions as a versatile 
antiviral restriction factor of human-pathogenic positive-strand RNA viruses. Moreover, 
this study has delineated the contributions of TRIM56’s B-box and coiled-coil domains 
as well as the entire C-terminal portion to its novel antiviral functions. The full picture of 
the molecular determinants underlying the observed antiviral effects sheds light on the 
mechanisms of action of TRIM56. 
 
We previously demonstrated that TRIM56 restricts the replication of BVDV (34). 
The close relatedness of DENV and YFV to BVDV is in line with their shared sensitivity 
to TRIM56’s antiviral actions. However, a seemingly contradicting observation 
previously made was that TRIM56 failed to inhibit hepatitis C virus (HCV) replication 
when overexpressed in human hepatoma Huh7 cells (34), the current cell culture model 
permitting efficient propagation of this virus. Exactly why TRIM56 was inefficient in 
curbing HCV (which is classified in the Hepacivirus genus within the family 
Flaviviridae) is unknown. However, it is important to point out that Huh7 cells have 
severely impaired antiviral responses (50,59). Perhaps one or more cellular cofactors 
required for TRIM56’s antiviral actions are missing in this particular cell line. Indirectly 
supporting this possibility, our group has previously found that ISG20, an IFN-inducible 
exonuclease, acted as a potent inhibitor of YFV replication in HEK293 cells but had no 
demonstrable antiviral activity in Huh7.5 cells, a subline of Huh7 cells (49). Clearly, 
examining the effect of TRIM56 on HCV in other cell hosts is warranted. Along this line, 
our attempts to establish HCV RNA replicons in the tet-inducible 293-FIT-T56 cells, 
however, have thus far turned up fruitless for unknown reasons, although HEK293 cells 
had previously been reported to support some selectable HCV RNA replicons at very low 
efficiencies (60). 
 
The discovery of TRIM56’s antiviral activity against a human coronavirus 
substantially broadens our understanding of the antiviral spectrum of this TRIM. 
Classified within the family Coronaviridae, HCoV-OC43 belongs to the genus 
Betacoronavirus that is shared by two other highly pathogenic coronaviruses, severe 
acute respiratory syndrome coronavirus and the newly-emerged Middle East respiratory 
syndrome coronavirus (61). Coronaviruses differ remarkably from Flaviviridae members 
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(e.g., YFV and DENV) in their transmission route, replication strategy and pathogenesis. 
The newly-uncovered broad antiviral spectrum of TRIM56 is consistent with its 
ubiquitous distribution across human tissues (34). Our novel findings raise the possibility 
that TRIM56 may also act to defend cells against other RNA viruses of significant public 
health concern.  
 
TRIM56 is among a handful of TRIMs that were recently shown to positively 
regulate innate antiviral pathways leading to IFNs production. Specifically, TRIM56 
promotes the TLR3-dependent signaling pathway that recognizes viral double-stranded 
(ds) RNAs by forming a complex with TRIF, independent of its E3 ligase activity (39). 
TRIM56 also interacts with and activates STING, enhancing the cytosolic dsDNA-
sensing pathway (39,58). However, data from the current study suggest a heightened IFN 
antiviral response does not underpin the antiviral effects of TRIM56 against YFV, 
DENV2 and HCoV-OC43 (Figure 3-3 and data not shown). Neither was it the case 
concerning the antiviral action of TRIM56 against BVDV (34). Consistent with IFN-
independent antiviral mechanisms, overexpression of TRIM56 failed to inhibit VSV (34) 
and EMCV (Figure 3-1F), two viruses widely used for IFN bioactivity assays because of 
their extreme sensitivity to very low amount of IFNs. Moreover, siRNA knockdown 
experiments ruled out the involvement of TRIF-, RIG-I- or STING-dependent 
mechanisms in exerting the antiviral actions of TRIM56 (Figure 3-4). Despite the strong 
in vitro evidence summarized above suggesting direct antiviral effects of TRIM56, the 
possibility cannot be fully excluded that TRIM56 may promote innate immune signaling 
to these RNA viruses in primary cells and/or immune sentinel cells in vivo, contributing 
to viral clearance systematically. Future studies in TRIM56-deficient mice will be needed 
to elucidate the exact contributions of this TRIM to host antiviral defense. It should be 
noted, as well, given the growing evidence suggesting participation of the STING-
dependent pathway in detecting DNA viruses and intracellular bacteria (62,63), it will be 
of interest in future studies to investigate whether TRIM56 is also involved in cellular 
processes that fend off these classes of parasites. 
 
Previous studies on other TRIMs have suggested that different TRIMs exert their 
antiviral effects via distinct mechanisms, which are dictated by different functional 
domains/portions. The N-terminal RING domain executes E3 ligase activity that 
promotes ubiquitination of viral proteins or host factors critical for viral replication, 
which are typically destined for proteasome-dependent degradation, as exemplified by 
TRIM22 E3 ligase-dependent degradation of influenza A virus nucleoprotein (29,30,33). 
The B-box, coiled-coil domain and C-terminal portion (or the special domains lying in 
it), mediate protein-protein interactions (or protein-nucleic acid interactions which is also 
possible) that can perturb viral life cycles. Examples of this category include B-box-
dependent TRIM15 restriction of murine leukemia virus (MLV) and the TRIM5α C-
terminal SPRY domain-mediated inhibition of human immunodeficiency virus (HIV) 
uncoating (32,64). Remarkably, different domain involvements can be well orchestrated 
to perform TRIM-mediated antiviral functions. For instance, a model of TRIM E3 Ub 
ligase function has been proposed in which the RING domain bearing catalytically-active 
E3 ligase determines recognition of E2 conjugating enzyme meanwhile the coiled-coil 
domain and C-terminal part ensure successful presentation of substrates to the E2 enzyme 
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(29,65). However, sometimes only one category of domain is involved in viral restriction. 
For example, TRIM15-mediated suppression of MLV requires its B-box domain alone, 
independent of the E3 ligase activity or the C-terminal SPRY domain (64). In the case of 
TRIM56, the overlapping and distinct domain requirement profiles unveiled in the 
current study may illuminate how TRIM56 renders cells resistant to three positive-strand 
RNA viruses from two distinct families.   
 
 TRIM56-mediated antiviral activities against YFV, DENV2 and HCoV-OC43 share 
the requirement for the RING domain (Figures 3-6, 3-7 and 3-9). However, they differ in 
the requirement of other molecular determinants. Specifically, while the E3 ligase 
activity was the only requirement for TRIM56-mediated anti-HCoV-OC43 action 
(Figure 3-9), the restriction of flaviviruses (YFV and DENV2) additionally depended on 
the integrity of the C-terminal region of TRIM56 (Figures 3-6 and 3-7). When it comes 
to the coiled-coil domain, our data show that this motif is dispensable for restricting 
DENV2 and HCoV-OC43 (Figures 3-7 and 3-9), but contributes, to some extent, to anti-
YFV activity (Figure 3-6). Why there is a difference in the involvement of this domain 
for anti-YFV and anti-DENV2 actions is unknown and will require further study. Given 
that the coiled-coil domain is indispensable for homo- and hetero-dimerization of TRIMs 
(66), I postulate that TRIM56 may not absolutely rely on self-oligomerization or its 
pairing with another TRIM to curb infections by the RNA viruses investigated herein 
except YFV. Of note, I did not observe a dependence on the B-box domain for any of the 
TRIM56-mediated antiviral activities (Figures 3-6, 3-7 and 3-9), suggesting little 
contribution from B-box to the antiviral actions against flaviviruses and coronavirus. 
Although with structural similarity to the RING domain, B-box is not necessary for 
TRIM/E2 interaction (65). Altogether, the complex domain requirement profiles revealed 
for TRIM56-mediated inhibition of distinct RNA viruses illustrate a remarkable example 
of host restriction factor evolution, and explain why this TRIM is able to protect cells 
from invasion by a broad range of positive-strand RNA viruses. 
 
Last but not the least, I discovered that TRIM56 restricts flaviviruses and HCoV-
OC43 by targeting distinct stages of the viral life cycle. Time-course intracellular viral 
RNA quantification data (Figures 3-10A and 3-10B) suggest that virus-cell receptor 
interaction or early cellular entry of these viruses was not affected, while accumulation of 
intracellular viral RNAs during replication of YFV but not HCoV-OC43 was retarded. 
Moreover, transient replicon assay using a DENV2 replicon confirmed that TRIM56 
curbs flavivirus RNA replication but not translation (Figure 3-10C). The effect on YFV 
and DENV2 thus mirrored with those observed with TRIM56 on BVDV RNA replicons 
(34), suggesting that TRIM56 commonly targets viruses in the family Flaviviridae at the 
intracellular RNA replication step. However, I cannot fully exclude the impact, if any, of 
TRIM56 on virion transport or RNA uncoating of YFV or DENV2 immediately after the 
early entry step. By contrast, the data that progeny viral yield but not intracellular viral 
RNA abundance was inhibited by TRIM56 during HCoV-OC43 infection point to an 
effect on the viral packaging/release stages, which slows down coronaviral spread. Of 
note, it has been reported that mouse TRIM56 inhibits HIV release from cells (64), 
setting a precedent for the ability of TRIM56 to act on this late step of viral infections. 
Although the underlying molecular details remain to be elucidated, the distinct 
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mechanisms of action TRIM56 adopts to inhibit flaviviruses and HCoV-OC43 are 
consistent with the differential requirements of the C-terminal portions of this TRIM. 
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CHAPTER 4.    THE C-TERMINAL TAIL OF TRIM56 DICTATES ANTIVIRAL 
RESTRICTION OF INFLUENZA A AND B VIRUSES BY IMPEDING VIRAL 
RNA SYNTHESIS1 
 
 
Introduction 
 
Classified within the family Orthomyxoviridae, influenza A and B viruses (IAV and 
IBV) are important respiratory pathogens responsible for significant morbidity and 
mortality worldwide (12-15). These viruses possess segmented, negative-strand RNA 
genomes that are encapsidated with nucleoprotein (NP) and bound with polymerase 
proteins, collectively known as viral ribonucleoprotein (vRNP) complexes (14,15). One 
striking feature of the influenza virus life cycle is that virus RNA (vRNA) synthesis takes 
place in the nucleus (15,20,21). After virion entry, trafficking of incoming vRNPs into 
the nucleus is an active process dependent on the nuclear import machinery, followed by 
initiation of virus transcription and replication (15). As is the case of most RNA viruses, 
replication of influenza viruses is error-prone, generating mutant viruses that can escape 
host immune responses and/or antiviral drugs. Despite intense research and antiviral drug 
development efforts, options to combat influenza are for the most part limited to those 
targeting the viral NA and M2 ion channel, and emergence of drug-resistant viral mutants 
is a pressing issue (15). Thus, studies on novel virus-host interactions that alter influenza 
virus fitness are warranted and may reveal new targets for therapeutic interventions. 
 
In response to virus assaults including infection by influenza viruses, host cells 
employ exquisitely intrinsic mechanisms to fend off the invader. The induction of type I 
and type III inteferons (IFNs) represents a major immediate antiviral response in 
mammalian cells and is initiated by several classes of pattern recognition receptors 
(PRRs) including the Toll-like receptors (TLRs) and retinoic-inducible gene-I (RIG-I)-
like receptors (1-4). These PRRs engage viral pathogen-associated molecular patterns, 
most notably viral RNAs, triggering signaling cascades that culminate in activation of 
two critical transcription factors -- interferon regulatory factor 3 (IRF3) and NF-κB, 
which play pivotal roles in the transcription of interferons and pro-inflammatory 
cytokines/chemokines, respectively (1-4). To circumvent this host defense mechanism, 
IAV blocks IRF3 activation by its multifunctional non-structural protein (NS)-1 to cease 
IFN production whereas it exploits activated NF-κB to regulate its viral RNA synthesis 
and promote inflammation (25,26).  In addition to the IFN system, host cells express, 
often constitutively, numerous antiviral proteins dubbed restriction factors, which act to 
curb different viral infections via distinct mechanisms (5). Among these, tripartite motif-
containing protein (TRIM) family members have recently garnered increasing attention, 
with several reported to participate in host defense against IAV (28-31).  
____________________________ 
 
1 Adapted with permission.  Liu B, Li NL, Shen Y, Bao X, Fabrizio T, Elbahesh H, 
Webby RJ, Li K. The C-terminal Tail of TRIM56 Dictates Antiviral Restriction of 
Influenza A and B Viruses by Impeding Viral RNA Synthesis. J Virol 2016. pii: 
JVI.03172-15. 
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TRIM family proteins are characterized by a highly conserved N-terminal RBCC 
(RING-B box-Coiled coil) motif and are believed to possess E3 ligase activity conferred 
by the RING domain. In contrast, TRIM’s C-terminal portions exhibit high variability in 
domain structures, based on which they are divided into up to 11 subfamilies (30,31). Of 
these, subfamily C-IV members, as exemplified by TRIM25 and TRIM22, harbor SPRY 
or/and PRY domains facilitating protein-protein interactions; TRIM-NHL proteins in 
subfamily C-VII, such as TRIM32 and TRIM71, possess NHL (NCL-1, HT2A and LIN-
41)-repeats mediating binding to RNAs/proteins (67). Functionally, TRIMs have been 
implicated in a broad array of cellular processes that range from cell growth, 
differentiation, oncogenesis, and more recently, to immunity (29,67-69). Of the 
immunity-regulating TRIMs reported to date, several play important roles in 
orchestrating PRR-mediated signaling cascades in response to viral invasions. A prime 
example is TRIM25, which promotes ubiquitination and activation of the PRR RIG-I to 
sense IAV infection and induce IFN expression (38). Acting in a different functional 
category, several TRIMs exhibit direct antiviral effects. For example, TRIM22 inhibits 
IAV by poly-ubiquitinating viral NP and targets it for proteasome-dependent degradation 
(33). Notably, both TRIM25 and TRIM22 depend on the RING-type E3 ligase activity to 
operate (29). 
 
Recent evidence suggests that TRIM56 (also referred to as T56) is a novel player in 
innate antiviral immunity (34,35,39). This TRIM protein belongs to the subfamily C-V 
because it lacks a well-characterized domain in the C-terminal half hitherto (28,29).  
TRIM56 promotes TLR3- and STING-mediated antiviral signaling pathways towards 
IFN induction via E3 Ub ligase-independent and -dependent mechanisms, respectively 
(39,58). Additionally, TRIM56 exerts its direct antiviral effects, which are dependent on 
its E3 ligase activity, on four positive-strand RNA viruses, including three members of 
the family Flaviviridae, i.e., bovine viral diarrhea virus (BVDV), yellow fever virus 
(YFV) and dengue virus serotype 2 (DENV2), and a coronavirus, human coronavirus-
OC43 (HCoV-OC43) (34,35). However, little is known regarding TRIM56’s antiviral 
spectrum against negative-strand RNA viruses, especially respiratory viruses such as 
influenza viruses, given the fact that TRIM56 is most abundantly expressed in the lung 
(34). 
 
In this study I demonstrate that TRIM56 is an intrinsic host restriction factor of 
influenza viruses. Intriguingly, this attribute was found to be uncoupled from TRIM56’s 
E3 ligase activity and the entire N-terminal TRIM motif was dispensable. Instead, the C-
terminal 63 residues were both necessary and sufficient to inhibit replication of both IAV 
and IBV. Moreover, I show that TRIM56 impedes influenza virus infection by hindering 
viral RNA synthesis by its C-terminal tail portion.  
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Results 
 
 
Ectopic Expression of TRIM56 Inhibits Propagation of IAV and IBV, but Not That 
of SeV or hMPV  
 
We had previously shown that TRIM56 is a restriction factor of four positive-strand 
RNA viruses, including three members of the Flaviviridae family (BVDV, YFV and 
DENV2) and a Coronaviridae family member (HCoV-OC43) (34,35). However, whether 
TRIM56 participates in host defense against negative-strand RNA viruses is largely 
unknown.  VSV (a Rhabadovirus) is the only negative-strand RNA virus that has been 
examined to date; the propagation of this virus was not affected by ectopic expression of 
TRIM56 (34). In this study, I set out to determine if manipulation of TRIM56 abundance 
alters propagation of influenza viruses, which are medically important viruses classified 
within the family Orthomyxoviridae.   
 
I first utilized HEK293-FIT-derived cells with tet-inducible expression of N-terminal 
HA-tagged TRIM56 (35) to examine the impact of TRIM56 overexpression on IAV. As 
shown in Figure 4-1A (left), negligible expression of HA-TRIM56 protein was observed 
in these cells when cultured in the absence of tet (-tet) but considerable HA-TRIM56 
protein was detected following tet addition to culture medium (+tet) (compare lane 1 vs 
2). When infected with influenza A/PR/8/34 virus at an MOI of 0.1, there was abundant 
viral NP antigen in -tet cells at 9 hpi (lane 3). However, NP expression was diminished in 
cells induced for HA-TRIM56 expression (+tet, lane 4). Consistent with this, progeny 
virus titer in supernatants of 293-FIT-T56 +tet cells were significantly decreased as 
compared with -tet cells (P < 0.001) (Figure 4-1A, right). This antiviral effect of 
TRIM56 persisted at later time points (i.e., 16, 24 and 48 hpi) (Figure 4-1B). 
Additionally, MDBK-T56 cells stably expressing Flag-tagged human TRIM56 were 
substantially less susceptible to influenza A/PR/8/34 virus than MDBK-Bsr cells that 
express a control retroviral vector, as evidenced by substantially reduced intracellular NP 
antigen expression (Figure 4-1C, lower right immunoblot panels), ~1-log fewer (P < 
0.01) progeny virions yielded in culture supernatants (Figure 4-1C, upper right panel), 
and significantly lower percentage of NP-positive cells (Figure 4-1C, left 
immunostaining panel). Furthermore, TRIM56’s antiviral effect against IAV was also 
observed in U2OS cells stably expressing TRIM56-Flag (U2OS-T56) compared with 
control cells (U2OS-Bsr) expressing a control vector (data not shown). To further 
corroborate this finding, I knocked down the ectopically expressed human TRIM56 in 
MDBK-T56 cells by lentiviral delivery of a TRIM56 shRNA (shT56). As shown in 
Figure 4-1D (lower immunoblot panel), TRIM56-Flag expression was reduced by 80% 
in the knockdown cells (MDBK-T56 shT56) compared with the control cells (MDBK-
T56 ctrl) transduced with a scrambled, negative control shRNA, concomitant with a 6-
fold increase (P < 0.05) in progeny virus production (MOI = 0.5, 24 hpi; Figure 4-1D, 
upper panel). Taken together, I conclude that ectopic expression of TRIM56 impedes 
IAV propagation. Importantly, this is a reproducible phenomenon, regardless of the 
expression system or cell type. 
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Figure 4-1. Ectopic expression of TRIM56 hinders propagation of IAV/IBV, but 
not infection by hMPV or Sendai virus. 
(A) (Left) HEK293-Flp-In T-REx-TRIM56 (293-FIT-T56) cells were cultured without 
(lanes 1 and 3, -tet) or with (lanes 2 and 4, +tet) (2 μg/ml) for 48 h, followed by mock-
infection (lanes 1 and 2) or infection with influenza A/PR/8/34 (H1N1) virus for 9 h 
(MOI = 0.1; lanes 3 and 4). For +tet cells (lanes 2 and 4), they were kept in tet-containing 
media until lysed for western blot. Expression of N-terminally HA-tagged TRIM56 was 
detected using an anti-HA tag antibody (Invivogen) that does not cross-react with viral 
HA of H1N1 influenza A viruses and expression of IAV NP detected by an anti-influenza 
A/WSN/33 (H1N1) NP mAb. Actin served as a loading control to demonstrate equal 
sample loading. (Right) Progeny virus production in culture supernatants of 293-FIT-T56 
cells with or without tet treatment at 9 hours post-infection (hpi) with influenza 
A/PR/8/34 virus (MOI = 0.1). (B) Progeny virus production in culture supernatants of 
293-FIT-T56 cells cultured with or without tet at 0, 8, 16, 24 and 48 hpi with influenza 
A/PR/8/34 virus (MOI = 0.1). (C) (Left side) Immunofluorescence staining of NP (using 
anti-influenza A/WSN/33 (H1N1) NP mAb) in MDBK cells stably expressing TRIM56-
Flag (T56) or a control retroviral vector (Bsr) at 24 hpi with A/PR/8/34 virus (MOI = 5). 
(Right side) Progeny virus titer in culture supernatants (upper) and NP and actin 
expression (lower) in lysates of infected cells under the same conditions as those on the 
left side. (D) (Lower) Immunoblot analysis of ectopically expressed human TRIM56 
(using anti-TRIM56 antibody) in MDBK-T56 cells transduced with lentiviruses encoding 
either an shRNA specifically targeting human TRIM56 (MDBK-T56 shT56) or a non-
targeting, scrambled control shRNA (MDBK-T56 Ctrl). (Upper) Progeny virus titers in 
culture supernatants of the indicated cells infected with influenza A/PR/8/34 virus for 24 
h (MOI = 0.5). (E) (Upper) Progeny virus production in culture supernatants of 293-FIT-
T56 cells with or without tet treatment at 24 hpi with influenza B/Florida/4/06 
(Yamagata) virus (MOI = 0.1). (Lower) Immunoblot analysis of HA-tagged TRIM56 
(using an anti-HA tag mAb (Invivogen) not cross-reacting with IBV HA) and viral HA 
(using an anti-influenza B/Hong Kong/8/73 HA pAb). Tubulin served as a loading 
control to demonstrate equal sample loading. (F) HeLa-FitA2-T56 cells with tet-regulated 
expression of HA-tagged TRIM56 were cultured with (lanes 3 and 4) or without tet (lanes 
1 and 2), followed by mock-infection (lanes 1 and 3) or infection by hMPV (MOI = 1, 
lanes 2 and 4) for 15 h. Cell lysates were subjected to immunoblot analysis of HA-tagged 
TRIM56 (using anti-HA tag mAb (clone 12CA5, Roche)) and viral proteins (using anti-
hMPV pAb). Asterisk denotes a nonspecific band. (G) 293-FIT-T56 cells cultured in the 
absence (-tet) or presence (+tet) of tetracycline were infected with Sendai virus (SeV) at 
indicated doses (1.6, 16 and 160 HAU/ml) for 8 h, followed by immunoblot analysis of 
HA-tagged TRIM56 (using anti-HA mAb (Invivogen)) and viral proteins (using anti-SeV 
pAb, which mainly reacted with SeV hemagglutinin-neuraminidase and nucleocapsid). 
Actin served as a loading control. Single, double and triple asterisks indicate that 
statistical differences exist between the indicated cells with a P value of < 0.05, < 0.01 
and < 0.001, respectively. 
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I next investigated if TRIM56’s antiviral effect could be extended to IBV. It was 
found that induction of TRIM56 expression in 293-FIT-T56 cells led to a sharp decline in 
viral HA antigen abundance as compared with -tet (uninduced) cells at 24 hpi with 
influenza B/Florida/4/06 virus (MOI = 0.1) (Figure 4-1E, lower panel). Concordant with 
this, progeny virus production in +tet cells was 7-fold (P < 0.05) lower than in -tet cells 
(Figure 4-1E, upper panel). Similar anti-IBV effect of TRIM56 overexpression was also 
observed at 8 and 12 hpi (MOI = 0.01) in HeLa-FitA2-T56 cells with tet-inducible 
expression of HA-TRIM56 (data not shown), again confirming that the phenomenon was 
not cell-type specific. Collectively, it was established that TRIM56, when ectopically 
expressed, curbs IBV infection. Of note, influenza viruses (IAV and IBV) represent the 
first negative-strand RNA virus family TRIM56 was found to inhibit. 
 
To determine whether TRIM56 also restricts other negative-strand RNA viruses, I 
studied the effects of TRIM56 overexpression on hMPV (Figure 4-1F) and SeV  
(Figure 4-1G), paramyxoviruses that cause respiratory infections in humans and rodents, 
respectively.  There was no inhibitory effect on viral protein expression following 
infection by either virus, when comparing cells induced for HA-TRIM56 expression and 
uninduced cells. The lack of an antiviral effect on these paramyxoviruses suggests that 
TRIM56 does not target negative-strand RNA viruses indiscriminately. Consistent with 
this concept, we previously demonstrated that TRIM56 overexpression does not inhibit 
VSV propagation (34). 
 
 
Knockdown of TRIM56 Augments Multiplication of Influenza Viruses 
 
To determine whether TRIM56 expressed at physiologic levels poses a barrier to 
infection by influenza viruses, I dissected the effect of TRIM56 knockdown on influenza 
virus propagation. Compared to control MDBK cells, MDBK-T56i cells with stable 
knockdown of endogenous TRIM56 (34; Figure 4-2A, left) supported substantially 
higher levels of viral NP expression and produced >1-log more (P < 0.01) progeny 
influenza A/PR/8/34 virions (Figure 4-2A, middle). In contrast, MDBK-T56i cells were 
not more permissive than control MDBK cells to infection by VSV-Luc, a recombinant 
VSV expressing luciferase as readout of viral replication (Figure 4-2A, right). These 
data lend further support to the notion that endogenous TRIM56 specifically hinders 
influenza virus infection. The same can be said regarding the impact of TRIM56 
depletion on IAV infection in HeLa cells (Figure 4-2B). I found that HeLa cells with 
stable knockdown of TRIM56 (shT56) yielded ~6-fold (P < 0.01) more progeny IAV 
than control cells. HeLa-shT56 cells also supported higher levels of viral HA protein 
expression (Figure 4-2C, immunoblot panels) and ~1-log more (P < 0.01) progeny 
influenza virus production (Figure 4-2C, upper panel) than did control cells, following 
IBV infection. Altogether, these data demonstrate that TRIM56 expressed at 
physiological levels puts a check on infection by influenza A and B viruses. 
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Figure 4-2. TRIM56 knockdown augments influenza virus multiplication. 
(A) (Left part) qPCR analysis of bovine TRIM56 (boT56) mRNA expression in control 
MDBK cells (Ctrl) and its derived cells (T56i) stably transfected with a boT56 shRNA. 
(Upper, middle part) Progeny virus production in culture supernatants of MDBK-Ctrl and 
MDBK-T56i cells at 24 hpi with influenza A/PR/8/34 virus (MOI = 5). (Lower, middle 
part) Immunoblot analysis of NP and actin expression in cell lysates under the conditions 
of the upper part. (Right part) MDBK-Ctrl cells and MDBK-T56i cells were infected with 
VSV-Luc at MOI of 0.2. At the indicated times, cells were lysed for firefly luciferase 
assay. (B) (Lower) Immunoblot analysis of human TRIM56 expression (using anti-
TRIM56 antibody) in HeLa-plkO.1 (Ctrl) cells stably transduced with a non-targeting, 
scrambled control shRNA or HeLa-shT56 (shT56) cells transduced with an shRNA 
specifically targeting TRIM56. (Upper) Progeny virus production in culture supernatants 
of the two cell lines at 8 hpi with influenza A/PR/8/34 virus (MOI = 0.01). (C) (Lower) 
Immunoblot analysis of TRIM56 expression (using anti-TRIM56 antibody) and viral HA 
levels (using anti-influenza B/Hong Kong/8/73 HA pAb) in HeLa-plkO.1 (Ctrl) or HeLa-
shT56 (shT56) cells at 8 hpi with influenza B/Florida/4/06 virus (MOI = 0.01). (Upper) 
Progeny virus production in culture supernatants of the cells under the same conditions as 
the lower immunoblot panel. Double asterisks indicate that statistical differences exist 
between the indicated cells with a P value of < 0.01. 
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The C-terminal Tail of TRIM56, but Not Its E3 Ligase Activity or the Other 
Portions of the Protein, Is Required for the Ability to Impede Influenza Virus 
Infection 
 
TRIM56 exerts antiviral actions against positive-strand RNA viruses of distinct 
families via overlapping and distinct molecular determinants (34,35). Specifically, while 
the TRIM56’s RING and the E3 ligase activity conferred by this domain are required to 
inhibit BVDV, flaviviruses and HCoV-OC43, the C-terminal portion (residues 621-755) 
is critical for restriction of BVDV and flaviviruses but dispensable for HCoV-OC43 
suppression (34,35). To determine which domains or portions of TRIM56 are required for 
its novel antiviral actions against negative-strand RNA viruses, I mapped the TRIM56 
molecular determinants which are essential for the restriction of influenza viruses, using 
HEK293-FIT-derived cell lines with tet-inducible expression of a series of HA-tagged 
TRIM56 mutants. The mutants included for analysis were the E3 Ub ligase-deficient 
CC21/24AA mutant, mutants lacking the RING (ΔRING), B-box (ΔB-box) or Coiled-
coil (ΔCoiled-coil) domains, respectively, and mutants possessing different deletions in 
the C-terminal portion -- Δ355-433, Δ621-695 and Δ693-750 (Figure 4-3A, left). The 
expression levels of these mutants have been confirmed to be comparable to that of wild-
type (WT) TRIM56 (35).  
 
When challenged with the influenza A/PR/8/34 virus at MOI of 0.1, an obvious 
inhibitory effect on influenza NP accumulation following tet induction (+tet) was 
observed at 9 or 27 hpi in HEK 293-FIT-T56 cells and in all of the mutant TRIM56-
inducible cells except the line that expresses the Δ693-750 mutant (Figure 4-3B). In 
agreement with the influenza NP immunoblot data, progeny virus production was 
curtailed by ~1-log by induction of WT TRIM56 (P <0.001) or any of the TRIM56 
mutant (P < 0.01), with the exception of the Δ693-750 mutant (Figure 4-3A, right). 
Thus, the very C-terminal tail portion of TRIM56 contains the sole determinant crucial 
for the anti-IAV activity. In stark contrast with what is required for flavivirus and 
coronavirus restriction, the E3 ligase activity of TRIM56 is dispensable for containing 
IAV.  
 
To confirm the important findings which were shown above, I made effort to gauge 
influenza NP expression and progeny virus production in MDBK cells stably expressing 
Flag-tagged, WT or mutant human TRIM56 following infection by influenza A/PR/8/34 
virus. As shown in Figure 4-3C (immuoblot data in lower panels), at 13 hpi (MOI = 3), 
abundant influenza NP antigen was detected in MDBK-Bsr cells expressing a control 
vector (lane 1). However, there was profound reduction in influenza NP expression in 
cells expressing WT TRIM56 (lane 3), the E3 Ub ligase-null CC21/24AA mutant (lane 
4), ΔRING (lane 5) and ΔCoiled-coil (lane 6) mutants. In contrast, influenza NP 
expression was not reduced, but increased (lane 7) as compared with parental MDBK 
cells (lane 2). Progeny influenza virus titer data (Figure 4-3C, bar graph in upper panel) 
were in accordance with the influenza NP immunoblot results. Collectively, the data 
gleaned from MDBK-derived cells mirrored those obtained from HEK 293-FIT-derived 
cells.  
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Figure 4-3. The restriction of IAV by TRIM56 relies on its C-terminal tail 
portion, but not on its E3 ligase activity or other parts of the protein. 
(A) (Left) Schematic representation of TRIM56 protein domains and the individual 
TRIM56 mutants investigated in this study. (Right) Progeny virus production in culture 
supernatants of 293-FIT-T56-WT or individual TRIM56 mutant cells cultured in the 
absence (-tet) or presence (+tet) of tet at 9 hpi with influenza A/PR/8/34 virus (MOI = 
0.1). (B) Immunoblot analysis of HA-tagged wild-type (WT) or mutant (mut) TRIM56 
(using an anti-HA tag Ab (Invivogen) not reacting with viral HA of H1N1 IAV) and NP 
protein abundance (using anti-influenza A/WSN/33 (H1N1) NP mAb) in 293-FIT-T56 
WT/Mut cells in the absence (odd numbered lanes) or presence (even numbered lanes) of 
tet, and mock-infected or infected with influenza A/PR/8/34 virus (MOI = 0.1) for 9 or 27 
h. Data from each cell line are presented in an immunoblot block (8 blocks in total, 
representing 8 different WT/mut TRIM56-inducible cell lines as shown in panel A). (C) 
(Lower) Immunoblot analysis of TRIM56 (using anti-human TRIM56 antibody) and NP 
protein abundance (using anti-influenza A/WSN/33 (H1N1) NP mAb) in parental MDBK 
as well as MDBK-derived cells stably expressing a control vector (Bsr), C-terminal Flag-
tagged human TRIM56 (WT) or its mutant versions infected with influenza A/PR/8/34 
virus for 13 h (MOI = 3). (Upper) Progeny viral titers in culture supernatants of the 
indicated MDBK-derived cell lines infected with influenza A/PR/8/34 virus (MOI = 3) 
for 13 h. Double and triple asterisks indicate that statistical differences exist between 
MDBK and WT/Mut T56 over-expressing cells, or between -tet and +tet cells with a P 
value of < 0.01 and < 0.001, respectively. 
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Consistently similar results were obtained when I determined progeny IBV 
production in HEK293-FIT-derived cells conditionally expressing WT TRIM56 or 
individual TRIM56 mutants (Figure 4-4). The ~1-log reduction in progeny virus yields 
(P values ranging from < 0.05 to < 0.001) in + tet cells compared with -tet cells at 24 hpi 
with the B/Florida/4/06 virus (MOI = 0.1) was abrogated only in cells harboring the 
Δ693-750 mutant. Altogether, the domain-mapping experiments in HEK293-FIT- and 
MDBK-derived cells reached the same conclusion that the very C-terminal tail region 
contains the sole prerequisite for TRIM56’s antiviral activity against IAV and IBV. The 
shared TRIM56 determinant in restricting both genera of influenza viruses is consistent 
with the similar replication strategies of these orthomyxoviruses, and suggests that 
TRIM56 adopts the same antiviral mechanism against IAV and IBV.  
 
 
TRIM56’s C-terminal Tail Is Sufficient to Curb Influenza Virus Infection 
 
Since our data showed that residues 693-750 at the C-terminal tail portion of TRIM56 
is essential for the anti-influenza function, I asked if peptides derived from TRIM56’s C-
terminal region are sufficient to confer influenza virus restriction. To this end, I 
established HEK293-FIT-derived cell lines with tet-inducible expression of HA-tagged 
TRIM56 fragment comprising the C-terminal 135 (i.e., aa 621-755, referred to as 
CTT135) and 63 (i.e., aa 693-755, referred to as CTT63) residues, respectively  
(Figure 4-5A-B). When infected with A/PR/8/34 virus (MOI = 0.1), induction of 
CTT135 expression led to substantial decline in NP expression and progeny virus 
production, which mirrored the effect of induction of TRIM56 expression (Figure 4-5C).  
Induction of CTT63 produced a similar effect on NP expression (Figure 4-5D), 
suggesting the 63 residues at the very C-terminal end of TRIM56 contain the minimal 
determinant for the antiviral function of the full-length protein. The same could be said 
when I infected cells with B/Florida/4/06 virus (Figure 4-5E). The shared TRIM56 
determinant governing the inhibitory effect on IAV and IBV implies that TRIM56 likely 
restricts both genera of influenza viruses via a similar mechanism. Thus, in subsequent 
experiments I utilized IAV to probe how TRIM56 executes its anti-influenza actions. 
 
 
TRIM56 Curtails Influenza Virus Propagation by Targeting Virus RNA Synthesis 
 
Following virus entry and uncoating steps, incoming influenza vRNPs are first 
transported into the nucleus, where viral RNA replication occurs (15,20,21). Directed by 
a trimeric viral RNA polymerase complex in association with NP, vRNAs serve as the 
templates for synthesis of mRNAs and cRNAs, with the latter becoming the templates for 
synthesis of progeny vRNAs. Viral mRNAs are then transported to the cytoplasm for 
translation into nascent viral proteins that are required for cRNA and vRNA synthesis  
(e.g., NP) and that serve structural and regulatory functions. At late stage of the infection, 
vRNAs are exported out of the nucleus for virion packaging and budding (15,26). To 
determine at which step(s) of the influenza viral life cycle TRIM56 acts, I performed 
single-cycle growth analysis of IAV infection. MDBK-T56 cells with stable expression 
of human TRIM56 and MDBK-Bsr cells (expressing the empty vector) were infected  
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Figure 4-4. TRIM56’s C-terminal tail is the only prerequisite for its anti-IBV 
function. 
Progeny virus production in culture supernatants of 293-FIT-derived, T56 WT or 
individual mutant cells in the absence (-tet) or presence (+tet) of tet at 24 hpi with 
influenza B/Florida/4/06 virus (MOI = 0.1). Single and triple asterisks indicate that 
statistical differences exist between -tet and +tet cells with a P value of < 0.05 and < 
0.001, respectively. 
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Figure 4-5. Expression of TRIM56’s C-terminal tail alone is sufficient to curb 
infection by IAV or IBV. 
(A) Schematic representation of putative NHL-like repeats in TRIM56’s C-terminal 
portion and two peptides derived from TRIM56’s C-terminal tail (CTT), i.e., TRIM56’s 
C-terminal 135 residues (CTT135) and 63 residues (CTT63). (B) Immunoblotting HA-
tagged WT TRIM56, CTT135 and CTT63 (using anti-HA tag mAb (Invivogen)), and 
actin in HEK293-Flp-In T-REx-derived cells with tet-inducible expression of HA-tagged 
WT TRIM56 (293-FIT-T56-WT), CTT135 (293-FIT-T56-CTT135) or CTT63 (293-FIT-
T56-CTT63) in the absence (-tet) or presence (+tet) of tet. (C) (Upper) Progeny virus 
titers in supernatants of 293-FIT-T56-WT or -CTT135 cells cultured with (+tet) or 
without tet (-tet) at 8 hpi with influenza A/PR/8/34 virus (MOI = 0.1). (Lower) 
Immunoblot analysis of NP (using anti-influenza A/WSN/33 (H1N1) NP mAb) and actin 
expression in the corresponding cell lysates. (D) Immunoblot analysis of NP (using anti-
influenza A/WSN/33 (H1N1) NP mAb) and actin expression in 293-FIT-T56-WT (left) 
or -CTT63 cells (right) cultured with (+tet) or without tet (-tet) at 8 hpi with influenza 
A/PR/8/34 virus (MOI = 0.1). (E) (Upper) Progeny virus titers in supernatants of 293-
FIT-T56-WT or -CTT63 cells cultured with (+tet) or without tet (-tet) at 24 hipi with 
influenza B/Florida/4/06 virus (MOI = 0.1). (Lower) Immunoblot analysis of viral HA 
(using anti-influenza B/Hong Kong/8/73 HA pAb) and actin expression in the 
corresponding cell lysates. Single asterisk indicates that statistical difference exists 
between -tet and +tet cells with a P value of < 0.05.  
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with influenza A/PR/8/34 virus at an MOI of 3, followed by a stringent wash in 0.9% 
NaCl (pH = 2.2) to remove extracellular virions that had not entered the cells. At 
1, 4, 8 and 12 hpi, cells were washed extensively with PBS to eliminate extracellular 
viruses and viral RNAs before they were lysed for total RNA extraction and qPCR 
analysis of intracellular levels of vRNA, cRNA and mRNA of M segment. At the same 
time, yields of progeny viruses in cell-free culture supernatants at 8 and 12 hpi were 
determined by TCID50 assay. 
 
At 1 hpi, intracellular vRNA levels of A/PR/8/34 virus were indistinguishable 
between MDBK-T56 and MDBK-Bsr cells (Figure 4-6A). In line with previous reports 
(26,53,70,71), I found at this early time point IAV had already initiated mRNA 
transcription and cRNA synthesis in MDBK-Bsr cells. However, the abundance of cRNA 
(Figure 4-6B) and mRNA (Figure 4-6C) was 3-fold and 7-fold lower, respectively, in 
MDBK-T56 cells, suggesting that viral mRNA transcription and cRNA synthesis were 
hindered in TRIM56-overexpressing cells. At 4 hpi when viral RNA synthesis occurs at a 
high rate (26,70,71), the abundance of vRNA rose by 5-fold compared to that at 1 hpi 
(Figure 4-6A), while cRNA (Figure 4-6B) and mRNA (Figure 4-6C) both climbed by 
>3 logs in MDBK-Bsr cells. In contrast, vRNA levels did not increase in MDBK-T56 
cells at 4 hpi, suggesting onset of vRNA synthesis was delayed (Figure 4-6A). Although 
cRNA and mRNA levels increased compared to 1 hpi, they were 61-fold and 88-fold 
lower, respectively, than those in MDBK-Bsr cells (Figure 4-6B-C). At 8 hpi when virus 
RNA synthesis had already finished (26,71), I found that levels of all three RNA species 
reached plateau in MDBK-Bsr cells as well in MDBK-T56 cells (as compared to 12 hpi). 
Nonetheless, vRNA, cRNA, or mRNA levels remained 4-7 fold lower in MDBK-T56 
cells at both 8 and 12 hpi (Figure 4-6A-C). These data show that there is a sustained 
influence on influenza virus vRNA, cRNA and mRNA levels throughout the life cycle in 
TRIM56-overexpressing cells.  
 
In the same experiments (at 8 and 12 hpi), I found that progeny virus production in 
MDBK-T56 cells was significantly reduced compared with MDBK-Bsr cells, and the 
extent of reduction was proportional to the decrease in vRNA synthesis (data not shown), 
indicating that the effect on viral RNA synthesis is primarily responsible for TRIM56’s 
anti-influenza action. Confirming that this observation is not cell-type specific, I obtained 
similar results when comparing time-course IAV RNA synthesis and progeny virus 
production between U2OS-T56 and U2OS-Bsr cells (data not shown). Therefore, it is 
confirmed that TRIM56 can curb influenza RNA synthesis in different cell types. 
 
 
The C-terminal Tail of TRIM56 Is Both Required and Sufficient for the 
Suppression of Influenza Virus RNA Synthesis 
 
To corroborate that TRIM56 impedes influenza virus RNA synthesis, I performed a 
luciferase reporter-based minigenome replication assay to measure IAV transcription and 
replication in HEK293-FIT-T56 cells with (+tet) and without (-tet) induction of HA-
tagged TRIM56. This system involves co-transfection of a total of six plasmids. Influenza 
RNA polymerase subunits (PB2, PB1, and PA) and NP derived from A/PR/8/34 virus are  
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Figure 4-6. TRIM56 hinders IAV propagation by inhibiting intracellular virus 
RNA synthesis. 
qPCR analysis of vRNA (A), cRNA (B) and mRNA (C) levels of matrix (M) gene 
segment of influenza A/PR/8/34 virus in MDBK cells stably expressing a control vector 
(Bsr) or TRIM56 (T56) at 1, 4, 8 and 12 hpi (MOI = 3). Single, double and triple 
asterisks indicate that statistical differences exist between Bsr and T56 cells with a P 
value of < 0.05, < 0.01 and < 0.001, respectively.  
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expressed from individual plasmids under control of a Pol II promoter. In a fifth plasmid, 
the Pol I promoter controls transcription of the antisense strand of Firefly luciferase RNA 
flanked by the untranslated regions of M segment vRNA (42). A sixth plasmid, pCMV-
RL, expresses Renilla luciferase from the CMV promoter, serving as an internal control 
for normalization of transfection efficiency. Since this assay was designed to mimic IAV 
transcription and replication steps, the Firefly/Renilla luc ratio (i.e., relative luciferase 
activity) is proportional to the level of influenza virus RNA synthesis (42,53,54). I found 
that at both 24 and 48 h post transfection (hpt), relative luciferase activity was 
consistently 2-fold higher (P < 0.01) in -tet cells than in +tet cells (Figure 4-7A), 
corroborating the qPCR data on vRNA levels (Figure 4-6) and lending further support 
for the notion that TRIM56 inhibits influenza virus RNA synthesis. Additional 
minigenome replication assays in Δ693-750 mutant TRIM56-inducible cells and its 
parental HEK293-FIT (Ctrl) cells (Figure 4-7B, 48 hpt) showed that this C-terminal tail 
deletion mutant loses the ability to suppress influenza viral RNA synthesis and ruled out 
any effect due to tetracycline treatment. Further, expression of the CTT63 alone was 
sufficient to inhibit influenza viral RNA synthesis (Figure 4-7C), demonstrating that the 
C-terminal tail of TRIM56 dictates the antiviral restriction of influenza viruses by 
hindering the viral RNA synthesis step. 
 
 
TRIM56 Moves into the Nucleus during Influenza Infection 
 
Because TRIM56 is a cytosolic protein in resting cells (34), I wondered how this 
protein impacts influenza virus RNA synthesis, which takes place in the nucleus. To 
address this question I determined the subcellular localization of GFP-TRIM56 in 
transiently transfected HeLa cells prior to and after A/PR/8/34 virus infection. As shown 
by the representative confocal fluorescence microscopy images (Figure 4-8A), while 
GFP-TRIM56 resided exclusively in the cytoplasm of mock-infected cells, GFP-TRIM56 
fluorescence was detected in both cytoplasm and nucleus in IAV-infected cells at 
different time points post infection. Interestingly, the subcellular distribution pattern of 
HA-tagged TRIM56-CTT63 mirrored that of full-length, HA-tagged TRIM56  
(Figure 4-8B). While there was no appreciable nuclear immunostaining of CTT63 in 
uninfected cells, a fraction of CTT63 was reproducibly found in the nucleus after IAV 
infection. The presence of TRIM56 and TRIM56-CTT63 in the nucleus of IAV-infected 
cells is consistent with their ability to impede influenza viral RNA synthesis. 
 
 
Discussion 
 
In this study, I have shown that TRIM56 is an intrinsic host restriction factor of 
influenza A and B viruses (Figure 4-1 and 4-2), expanding the antiviral spectrum of this 
TRIM to include the Orthomyxoviridae family of segmented, negative-strand RNA 
viruses. Ectopic expression of TRIM56 impeded propagation of these medically 
important respiratory pathogens (Figure 4-1), while silencing of endogenous TRIM56 
expression had the opposite effect (Figure 4-2). Importantly, these findings were 
reproduced in multiple cell types, irrespective of the expression system. Moreover, the  
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Figure 4-7. The C-terminal tail portion is required for TRIM56 suppression of 
influenza virus RNA synthesis. 
(A) Luciferase (luc) reporter-based minigenome replication assay of IAV RNA synthesis 
was performed in 293-FIT-T56 cells cultured in the presence (+tet) or absence (-tet) of tet 
at 24 and 48 h post co-transfection (hpt) with polymerase II-driven pHW plasmids 
expressing PB2, PB1, PA and NP, a polymerase I-driven luc reporter plasmid pHY-Luci, 
and a CMV promoter-driven plasmid expressing the Renilla luc (pRL-CMV, serving as 
an internal control for normalization of transfection efficiency). (B) Luciferase reporter-
based minigenome replication assay of IAV RNA synthesis in parental 293-FIT (Ctrl), 
293-FIT-T56 (WT), or 293-FIT-T56-Δ693-750 (Δ693-750) cells cultured with (+tet) or 
without tet (-tet) at 48 hpt. (C) Luciferase reporter-based minigenome replication assay of 
IAV RNA synthesis in 293-FIT-T56 (WT) or 293-FIT-T56-CTT63 (CTT63) cells 
cultured with (+tet) or without tet (-tet) at 48 hpt. Double and triple asterisks indicate that 
statistical differences exist between -tet and +tet cells with a P value of < 0.01 and < 
0.001, respectively. 
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Figure 4-8. TRIM56 and TRIM56-CTT63 move into the nucleus after IAV 
infection. 
(A) HeLa cells transiently transfected with an N-terminal GFP-tagged TRIM56 (GFP-
T56) plasmid was mock-infected or infected with influenza A/PR/8/34 virus for 4, 8 and 
16 h (MOI = 3), followed by immunostaining of NP (using anti-influenza A/WSN/33 
(H1N1) NP mAb). The subcellular localizations of GFP-T56 (green fluorescence) and NP 
(red fluorescence) were examined by confocal microscopy. Nuclei were counterstained 
blue with DAPI (4',6-diamidino-2-phenylindole). A scale bar represents 10 μm. (B) 293-
FIT-T56 or 293-FIT-T56-CTT63 cells were cultured in the presence of tet to induce 
expression of HA-tagged, TRIM56 (WT) or TRIM56-CTT63, followed by mock 
infection or infection with influenza A/PR/8/34 virus for 16 h (MOI = 3). HA-tagged 
TRIM56 and TRIM56-CTT63 were immunostained with an anti-HA tag mAb 
(Invivogen), and IAV matrix (M) proteins with a goat anti-matrix antiserum. The 
subcellular localization of HA-tagged WT TRIM56 and TRIM56-CTT63 (green 
fluorescence) and M (red fluorescence) proteins was examined by confocal microscopy. 
Nuclei were counterstained blue with DAPI. Scale bars represent 5 μm. 
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antiviral effect was specific for influenza viruses since TRIM56 did not inhibit SeV or 
hMPV (Figure 4-1), paramyxoviruses that cause respiratory infections in mice and 
humans, respectively. To our knowledge, this is the first study that demonstrates TRIM56 
targets negative-strand RNA viruses for inhibition. 
 
TRIM56 positively regulates innate antiviral signaling through TLR3- and STING-
dependent pathways. Specifically, TRIM56 forms a complex with TRIF, the TLR3 
adaptor, via its C-terminal region, promoting IRF3 activation and subsequent IFN 
response in ways independent of its E3 ligase activity (39). In contrast, the mechanism 
underlying the augmentation of STING-dependent IFN-induction pathway is distinct. In 
this case TRIM56 associates with STING and acts as an E3 ligase that promotes Lys63-
linked ubiquitination of STING, thereby enhancing cytosolic DNA-induced IFN 
production (58). In previous studies (34,35) we have shown that a heightened IFN 
response is not responsible for TRIM56-mediated inhibition of four positive-strand RNA 
viruses, BVDV, YFV, DENV2 or HCoV-OC43. This may be also the case for the novel 
anti-influenza activity of TRIM56 described in this study. First, I found no evidence of 
IFN induction or upregulation of ISGs in all cell types examined in this study following 
IAV (A/PR/8/34) infection, regardless of TRIM56 expression status (data not shown). 
This was not surprising given that IAV encodes multiple IFN antagonists, with NS1 
being the most potent and characterized one (25,72). Second, in cell culture innate 
antiviral response to IAV is primarily mediated by RIG-I while TLR3 plays a more 
proinflammatory role (22,73). However, TRIM56 does not contribute to or regulate RIG-
I/MDA5 signaling (39). Third, although STING-dependent pathway significantly 
contributes to host defense against DNA viruses and bacterial infections, direct evidence 
for this pathway in fending off RNA virus infections is lacking (58,62). Also, it is worth 
noting that I demonstrated the anti-influenza effect of TRIM56 in cell lines derived from 
HEK293 cells, which have undetectable STING protein expression (35). 
 
Of >70 TRIMs, two (TRIM22 and TRIM32) have been shown to inhibit influenza 
virus. Both critically hinge on the E3 ligase activity to operate by promoting viral protein 
degradation, with TRIM22 targeting NP (33) while TRIM32 acting on PB1 (74). 
However, TRIM56’s anti-influenza mechanism is distinct, which appears to be 
completely uncoupled from the E3 ligase activity and does not require the RING, B-box, 
or coiled-coil domains, either (Figure 4-3 and 4-4). This E3 ligase-independent 
mechanism is also in stark contrast to what is known about the antiviral activities of 
TRIM56 against flaviviruses and HCoV-OC43 (35). Remarkably, a TRIM56 fragment of 
as few as 63 residues at the C-terminus of the protein recapitulated the anti-influenza 
effect imposed by full-length TRIM56 (Figure 4-5), indicating that a fully functional 
motif mediating influenza virus restriction is encoded by this small portion of the protein. 
Given its small footprint, this anti-influenza determinant may be amenable to therapeutic 
manipulations. Additional, refined mapping and codon optimization may lead to a 
TRIM56-derived peptide/small molecule that has broad activity against different 
influenza viruses, since both IAV and IBV are susceptible to TRIM56’s action. 
 
Our time-course viral RNA quantification data (Figure 4-6) and influenza 
minigenome replication assay (Figure 4-7) show that TRIM56 specifically inhibits 
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influenza viral RNA synthesis by its C-terminal tail portion. Consistent with the fact that 
influenza viral RNA synthesis occurs in the nucleus, I found that a fraction of TRIM56 
localized into the nucleus in IAV-infected cells, in contrast with the exclusively cytosolic 
distribution of TRIM56 in uninfected cells (Figure 4-8). However, it is unknown whether 
the nuclear translocation of TRIM56 following influenza virus infection is an active, 
coordinate cellular process to combat the virus, or that TRIM56 is passively imported 
into or retained in the nucleus while it is associated with viral RNPs or host factors 
recruited to the RNPs. Further studies will be required to clarify this. Interestingly, 
TRIM32, which is another IAV-inhibitory TRIM, translocates to the nucleus following 
IAV infection as a result of its association with and retention by viral PB1 protein (74). In 
addition, a search using the NCBI conserved domain database showed that there exists 
sequence homology between the C-terminal residues 521-748 of TRIM56 and the NHL 
repeats of several well-characterized TRIM-NHL proteins (TRIM2, TRIM3, TRIM32 
and TRIM71) (Figure 4-9) (75,76). Of note, some of these TRIM-NHL proteins have the 
ability to regulate RNA abundance and metabolism (75,76), raising the possibility that 
TRIM56 might bear a similar function. Further investigation is still required to elucidate 
precisely how TRIM56 hinders influenza virus RNA synthesis, knowledge of which will 
provide new insights into factors and molecular interactions that control this vital step in 
influenza virus life cycle. 
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Figure 4-9. Sequence alignment of the C-terminal portion of TRIM56 with the 
NHL repeats of well-characterized TRIM-NHL proteins. 
The C-terminal amino acid sequence of TRIM56 (GenBank ID: NP_112223) was aligned 
and compared with the NHL repeat sequences of the following TRIM-NHL proteins, 
including NCL-1 (Swiss-Prot P34611), LIN-41 (Swiss-Prot Q9U489), KIAA0517 
(GenBank ID: BAA25443), Brat (GenBank AAF53771), TRIM3 (GenBank ID: 
NP_001234936), TRIM2 (GenBank ID: NP_056086) and TRIM71 (GenBank ID: 
NP_001034200). The numbering of the repeats in each protein was indicated as blades I-
VI. Numbers show the beginning (left) and ending (right) positions of each repeat of the 
proteins. Resides that are >50% conserved are highlighted by shade in color. Consensus 
residues at each conserved amino acid positions across different blades are shown at the 
bottom in the consensus sequence, in which “h” represents the hydrophobic residues 
isoleucine, leucine and valine. Asterisks denote the stop codon. 
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CHAPTER 5.    MOLECULAR DETERMINANTS GOVERNING TRIM56-
MEDIATED POSITIVE REGULATION OF THE TLR3 ANTIVIRAL 
SIGNALING PATHWAY 
 
 
Introduction 
 
 In response to viral invasion, the innate immune system constitutes a front line of 
host defense armed with multi-layered mechanisms. Of these, pattern recognition 
receptors (PRR), such as Toll-like receptors (TLRs) and retinoic-inducible gene-I (RIG-
I)-like receptors, play important roles in recognizing viral nucleic acids as a major class 
of viral pathogen-associated molecular patterns. That recognition triggers intracellular 
signaling pathways that culminate in activation of interferon regulatory factor 3 (IRF3) 
and NF-κB (1,2). These two transcription factors play pivotal parts in production of 
interferons (IFNs) and pro-inflammatory cytokines/chemokines. Type I IFNs (IFN-β and 
IFN-α) further induce hundreds of IFN-stimulated genes (ISGs) to establish an antiviral 
state restricting viral propagation and spread (1-4).  
 
Over the past decade, TRIM family members as intracellular restriction factors are 
increasingly recognized as active players in antiviral innate immunity (28-31). 
Structurally, TRIMs possess a highly conserved arrangement of domains in the N-
terminal RBCC motif (i.e., RING, B-box and coiled-coil domains), but their C-terminal 
tails vary. In general, RING domains confer TRIMs with E3 ubiquitin (Ub) ligase 
activity. B-box domains are zinc-binding motifs while coiled-coil domains facilitate self-
association and oligomerization and act as scaffolds for recruitment and formation of 
multi-protein complexes (30,31). Much attention has been paid to delineate direct 
antiviral roles of the TRIMs contributing to host restriction of specific types of viruses by 
targeting various steps in the viral life cycle. As an example, TRIM22 promotes 
polyubiquitination of the NP of influenza A virus (IAV) and targets it for proteasome-
dependent degradation (33). Work from our group has revealed that TRIM56 is a 
versatile antiviral host factor that restricts distinct RNA viruses including human 
coronavirus-OC43 and several members of the family Flaviviridae, via overlapping and 
distinct molecular determinants, (34,35). I recently found that TRIM56 also restricts 
influenza A and B viruses by suppressing viral RNA synthesis via its C-terminal tail, 
independent of the E3 ligase activity and other portions of TRIM56 (36). 
 
Recently, the “indirect” antiviral roles of various TRIMs, i.e., through positively 
regulating innate antiviral immune signaling pathways and augmenting IFN responses, 
have begun to be appreciated. Versteeg et. al reported that approximately half of the 75 
TRIMs have the ability to act at different junctures in innate immune signaling pathways, 
thereby promoting antiviral responses (37). In this group of TRIMs, TRIM25 depends 
upon its E3 ligase activity to ubiquitinate and activate RIG-I, thereby potentiating the 
RIG-I-mediated signaling pathway and downstream IFN induction (38,77). As another 
example, TRIM56 heightens cytosolic dsDNA-stimulated IFN production by interacting 
with and ubiquitinating stimulator of IFN genes (STING), an endoplasmic reticulum 
residing adaptor protein for innate immune signaling (58). Interestingly, our lab has 
 62 
shown that TRIM56 also promotes viral activation of IRF3 via the TLR3 pathway. In this 
case TRIM56 operates independent of its E3 ligase activity or the entire RING domain 
but, instead, involves an association with the TLR3 adaptor protein, i.e., TIR-domain-
containing adapter-inducing IFN-β (TRIF), via its C-terminal region (39). However, the 
precise mechanism by which TRIM56 positively modulates TLR3 signaling remains 
elusive. Also unclear is the detailed TRIM56 determinants governing this property. In 
this study, I made efforts to delineate roles of the coiled-coil domain and several putative 
phosphorylation sites residing in the C-terminal region of TRIM56 in the up-regulation of 
TLR3-dependent antiviral immunity. 
 
 
Results 
 
 
TRIM56 Promotes TLR3-mediated, IRF3- or NF-κB-dependent Signaling Pathway 
via Forming a Complex with TRIF  
 
We have previously reported that human TRIM56 positively regulates TLR3-
mediated IRF3-dependent signaling pathway (39). Bioinformatic analysis suggests there 
is 81% amino acid (aa) identity between human (here referred to as hTRIM56 or hT56) 
and murine TRIM56 (here referred to as mTRIM56 or mT56), though the latter is 22-aa 
shorter than the former. I wondered if mTRIM56 would have a similar property as 
hTRIM56 for regulating TLR3 signaling. To this end, dsRNA-induced IFN-β promoter 
activity with or without ectopic expression of mTRIM56 was determined (Figure 5-1A). 
Compared with the control vector, ectopic expression of mTRIM56 enhanced poly-I:C-
induced IFN-β promoter activity by 5.2 folds (P < 0.00001), while at the same time 
overexpression of hTRIM56 augmented IFN-β promoter activity by 2.6 folds (P < 0.001, 
Figure 5-1A, right). This data suggest that mTRIM56 is a stronger, positive regulator of 
TLR3 signaling than hTRIM56.  
 
Previously we found TRIM56 acts at the level of TRIF to modulate the TLR3 
signaling pathway. I reasoned that TRIM56 may also influence the activation of NF-κB, 
another transcription factor downstream of TRIF in the TLR3 signaling pathway. As 
expected, TRIM56 overexpression heightened NF-κB-dependent PRDII promoter 
activation following the TLR3 engagement. However, it had no effect on PRDII promoter 
activation induced by TNF-α- or IL-1β (Figure 5-1B). Thus, TRIM56 specifically 
positively regulates NF-κB activation through TLR3 signaling pathway. This evidence 
also confirmed that TRIM56 specifically acts on the TLR3 pathway prior to the 
bifurcation of NF-κB and IRF3. Consistent with this, I detected endogenous TRIM56 and 
TRIF proteins associated with each other early (0.5 - 2 hours) following exposure to 
extracellular poly-I:C, when there was no up-regulation of ISG56 (Figure 5-1C). 
Altogether, the aforementioned experiments corroborated that TRIM56 is a positive 
regulator of TLR3-mediated IRF3- and NF-κB-dependent signaling via its interaction 
with TRIF. 
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Figure 5-1. TRIM56 positively regulates TLR3-mediated IRF3- or NF-κB-
dependent signaling pathway by forming a complex with TRIF. 
(A) (Left) Immunoblot analysis of the expression of vectors encoding C-terminally V5-
tagged mouse TRIM56 (mT56-V5) and human TRIM56 (hT56-V5) (using mouse anti-
V5 monoclonal antibody (mAb)) in human embryo kidney (HEK) 293 cells. Actin serves 
as loading control. (Right) HEK293-TLR3 cells which ectopically express TLR3 were 
co-transfected with a plasmid encoding hT56 or mT56, or the corresponding empty 
vector (vector), as well as internal control plasmid pRL-TK and reporter plasmid IFN-β-
luc, followed by mock treatment or treatment with poly-I:C (pIC) for 8 h. Dual luciferase 
(luc) reporter assay was then performed to measure the promoter activation. (B) (Left) 
Immunoblot analysis of the ectopic expression of N-terminally Flag-HA-tagged TRIM56 
(FH-T56) (using mouse anti-HA mAb) in HEK293-TLR3-YFP (293-T3Y)-derived cells 
over-expressing FH-TRIM56 (293-T3Y-FH-T56). HEK293-T3Y-FH-T56 and its 
parental 293-T3Y cells were co-transfected with internal control plasmid pRL-TK and 
reporter plasmid IFN-β-luc (middle), or NF-κB responsive reporter plasmid PRDII-luc 
(right), followed by mock treatment or treatment with TNF-α, IL-1β or poly-I:C for 8 h. 
Dual luc reporter assay was then performed to measure the corresponding promoter 
activation. (C) Co-immunoprecipitation (co-IP) analysis of the interaction between 
endogenous TRIM56 with endogenous TRIF in HeLa cells at the indicated time points 
post poly-I:C treatment. Cell lysates were immunoprecipitated (IP) with anti-TRIM56 
polyclonal Ab (pAb), followed by immunoblotting (IB) with anti-TRIF or anti-TRIM56. 
The upper blot showed expression of TRIM, TRIF and IFN-stimulated gene 56 in cell 
lysates. Single asterisk indicates that statistical differences exist between mock- and poly-
I:C-treated cells with a P value of < 0.05. N.S., not statistically significant. 
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The Coiled-coil Domain and Residues 431-610 of TRIM56, but Not B-box or 
Residues 355-433, Are Critical for Enhancing TLR3-mediated IRF3- or NF-κB-
dependent Signaling  
 
We have previously demonstrated that TRIM56’s C-terminal end (aa 621-750) is 
critical for its positive regulation of TLR3-mediated IRF3-dependent signaling, while the 
E3 ligase activity and the entire RING domain are dispensable (39). However, the 
contribution of other portions of TRIM56 to this biological process is unknown. To better 
understand this, I measured poly-I:C-induced IFN-β promoter activities after transient 
expression of WT and various mutant TRIM56-V5 (Figure 5-2A). The mutants studied 
in this assay included those lacking the RING domain (referred to as ΔRING), B-box 
domain (referred to as ΔB-box), and all (ΔCoiled-coil) or part (Δ211-284 and Δ290-353) 
of the coiled-coil domain, respectively, and mutants bearing different deletions in the C-
terminal portion – Δ355-433 (lacking aa 355-433), Δ431-519 (lacking aa 431-519), 
Δ515-610 (lacking aa 515-610), Δ693-750 (lacking aa 693-750) and Δ369-742 (lacking 
aa 369-742). In addition, we examined the Δ2-363 mutant, which lacked residues 2-363  
thus losing the entire RBCC motif and a stretch of downstream sequences. The 
expression levels of these V5-tagged TRIM56 mutants were comparable to that of WT 
TRIM56 (data not shown; 34). Confirming our previous observation (39), the ΔRING 
mutant retained the ability to promote TLR3 signaling, acting similarly to  WT TRIM56 
whereas deletions in the C-terminal end (Δ693-750) abolished TRIM56’s ability to 
promote TLR3 signaling (P < 0.01, Figure 5-2A). Consistent with the latter result, the 
Δ369-742 mutant bearing a larger deletion in the C-terminal region (i.e., lacking nearly 
the C-terminal half of TRIM56) was also devoid of such capability (Fig. 5-2A). 
Interestingly, I found that the C-terminal portion of TRIM56 required for positive 
regulation of TLR3 signaling also included aa 431-610, since ectopic expression of Δ431-
519 and Δ515-610, but not Δ355-433, failed to augment TLR3-mediated IFN-β promoter 
activation, as compared with WT TRIM56 (P < 0.01), respectively. As to the N-terminal 
domains, ΔB-box was found to maintain the ability to enhance poly-I:C-induced IFN-β 
promoter activity. In contrast, Δ2-363 lacking the RBCC motif was unable to do so, 
suggesting a requirement for the coiled-coil domain. Confirming this notion, deletions of 
the entire coiled-coil (ΔCoiled-coil) or part of this domain (Δ211-284 and Δ290-353) 
abolished the function of TRIM56 in heightening TLR3 signaling (P < 0.01 to < 0.001). 
In aggregate, these data demonstrated that the integrity of the C-terminal portion 
spanning aa 431-750 is critical for the ability of TRIM56 to promote TLR3 signaling, as 
is the coiled-coil domain. However, the B-box is dispensable. These data were confirmed 
by examining TLR3-mediated activation of  IFN-β or IL-29 (IFN-λ1) promoters in 293-
FIT-T56 WT/Mut cells with tet-inducible expression of HA-tagged WT/mut TRIM56 
(Figure 5-2B) .  
 
TRIM56 can self-associate to form dimers, and the coiled-coil domain has been 
reported to mediate formation of anti-parallel dimers for TRIM molecules (34,66). To 
ascertain that the ΔB-box and Δ355-433 TRIM56 mutants are indeed capable of 
promoting TLR3 signaling, one has to exclude the possibility that functions of these 
mutants are dependent upon their pairing with endogenous, WT TRIM56. Our previous 
(36) and current qPCR data (Figure 5-2C, bottom) suggest that the mRNA level of the 
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Figure 5-2. TRIM56’s coiled-coil domain and residues 431-610, but not the B-box 
or residues 355-433, are required for its augmentation of TLR3-mediated IRF3-
dependent signaling pathway. 
(A) (Left) Schematic representation of wild-type (WT) and various TRIM56 mutants to 
be investigated in this study. R, B and CC represent RING, B-box and Coiled-coil 
domains, respectively. (Right) HEK293-TLR3 cells were co-transfected with an empty 
vector or vectors encoding WT and various mutant TRIM56-V5, as well as internal 
control plasmid pRL-TK and reporter plasmid IFN-β-luc, followed by mock- or poly-I:C-
treatment (for 8 h) and dual luc reporter assay. (B) Tetracycline (tet)-inducible HEK293-
Flp-In-T Rex (FIT)-derived cells conditionally expressing N-terminally HA-tagged, WT 
and mutant (mut) TRIM56 (HEK293-FIT-T56 WT/Mut) in the absence (-tet) or presence 
(+tet) of tet, were co-transfected with TLR3-encoding vector, pRL-TK and reporter 
plasmid IFN-β-luc (upper part) or IL-29-luc (lower part), followed by mock- or poly-I:C-
treatment (for 8 h) and dual luc reporter assay. (C) (Top) Immunoblot analysis of 
expression levels of endogenous and exogenously overexpressed (HA-tagged) TRIM56 
(using anti-TRIM56) in HEK293-FIT-T56 cells with (+tet) or without (-tet) tet treatment 
for 48 h. qRT-PCR was carried out to measure the abundance of endogenous TRIM56 
transcript (middle, using primers amplifying the 3’ UTR of TRIM56 mRNA), total 
TRIM56 transcript including the endogenous and exogenously overexpressed TRIM56 
mRNAs (bottom, using primers amplifying the coding region of TRIM56 mRNA) in 293-
FIT-T56 cells cultured with (+tet) or without (-tet) tet, and transfected with a negative 
control siRNA (Ctrl) or siRNA targeting 3’ UTR of TRIM56 (siT56-UTR). Note that (1) 
in -tet cells only endogenous, untagged TRIM56 was detected, while in +tet cells both 
forms of TRIM56 were visible. Densitometry analysis of the immunoblotting data show 
that the total TRIM56/actin arbitrary units for +tet cells were 12-fold of that for -tet cells; 
(2)  the siT56-UTR merely silenced the expression of the endogenous TRIM56 transcript 
but not that of the exogenously introduced (tet-inducible) TRIM56 which expressed only 
the coding region of the gene. (D) HEK293-FIT-T56 WT/Mut cells with (+tet) or without 
(-tet) tet were co-transfected siT56-UTR or the negative control siRNA (Ctrl), as well as 
a TLR3-encoding vector, pRL-TK and IFN-β-luc, followed by mock- and poly-I:C-
treatment (for 8 h) and dual luc reporter assay. Statistical analysis was performed 
between WT TRIM56 and vector or mutant TRIM56 after poly-I:C treatment in (A), 
between poly-I:C-treated -tet and +tet cells in (B) or (D), or between ctrl and siT56-UTR 
groups in (C) or (D). Single, double and triple asterisks denote that statistical differences 
exist with a P value of < 0.05, < 0.01 and < 0.001, respectively. N.S., not statistically 
significant. 
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exogenously introduced HA-tagged TRIM56 in cells cultured in the presence of tet (+tet) 
is ~10-15-fold higher than the endogenous TRIM56 transcript level (in cells cultured in 
the absence of tet (-tet)). The protein expression data are in line with the mRNA data, as 
shown in Figure 5-2C (top). When I efficiently silenced the expression of endogenous 
WT TRIM56 by transfecting cells with an siRNA (siT56-UTR) specifically targeting the 
3’ UTR of the endogenous TRIM56 transcript (Figure 5-2C), expression of the ΔB-box 
or Δ355-433 mutant was still able to augment poly-I:C-induced IFN-beta promoter 
activity (Figure 5-2D). Similar observation was also made when performing this assay 
with IL-29-luc (data not shown). These data confirm that the B-box and aa 355-433 are 
dispensable for the function of TRIM56 in promoting TLR3-mediated, IRF3-dependent 
signaling. I found a similar TRIM56 domain requirement profile for modulation of 
TLR3-mediated NF-κB activation (Figure 5-3), which is in agreement with our earlier 
finding that TRIM56 acts on the TLR3 pathway prior to the bifurcation of NF-κB and 
IRF3. 
 
 
Putative Phosphorylation Sites S471, S475 and S710 Are Required for TRIM56-
mediated Positive Regulation of TLR3 Signaling 
 
The C-terminal tail of TRIM56 has been shown to be indispensable for modulation of 
TLR3 signaling. Recently I have found there are four conserved serines in the C-terminal 
portions of human and murine TRIM56 (Figure 5-4A), which have been identified as 
phosphorylation sites in previous global proteomic studies (78-83). Specifically, the 
cluster of three putative phosphorylation sites (S469, S471 and S475) and S710 fall into 
aa 431-519 and aa 693-750, respectively, regions found to be essential for TRIM56’s 
ability to augment TLR3 signaling (Figures 5-2A and 5-3; 39).  
 
To determine if residue S710 plays a role in modulation of TLR3 signaling, vectors 
encoding TRIM56-V5 bearing S710A and S710D substitutions, respectively, were 
constructed in pCDNA3.1 backbone. These S710 mutants were expressed at comparable 
levels to that of WT TRIM56 or Δ693-750 in transfected cells as determined by 
immunoblotting (Figure 5-4B). I found that S710A mutation significantly (P < 0.01) 
reduced TRIM56-mediated up-regulation of poly-I:C-stimulated IFN-β promoter activity 
in HEK293-TLR3 cells to an extent similar to the Δ693-750 deletion, suggesting 
TRIM56-S710 is important for positive regulation of TLR3 signaling (Figure 5-4C, left). 
Similarly, an alanine mutation (S689A) on mTRIM56-S689, the counterpart of hTRIM56 
S710, also significantly impaired mTRIM56’s ability to heighten TLR3 signaling 
(Figure 5-4C, right). To further investigate the role of putative phosphorylation on 
TRIM56-S710 in regulating TLR3 signaling, I expressed WT TRIM56 and the S710 
mutants in HeLa-shT56 093 (clone #9) cells stably transduced with an shRNA 
specifically targeting the 3’UTR of TRIM56 transcripts, which were not present in WT 
and mutant TRIM56 expression constructs. As shown in Figure 5-4D (left), I confirmed 
the knockdown efficiency of endogenous TRIM56 in HeLa-shT56 093 (clone #9) cells 
(compare lane 9 with lane 1 or 2). Consistent with this, as shown in Figure 5-4D (right), 
poly-I:C-stimulated IFN-β promoter activity significantly diminished in HeLa-shT56 093 
cells  
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Figure 5-3. TRIM56’s coiled-coil domain and residues 431-610, but not the B-box 
or residues 355-433, are critical for its potentiation of TLR3-mediated NF-κB-
dependent signaling pathway. 
HEK293-TLR3 cells were co-transfected with an empty vector or vectors encoding WT 
and various mutant TRIM56-V5, as well as internal control plasmid pRL-TK and NF-κB 
responsive reporter plasmid PRDII-luc, followed by mock- or poly-I:C-treatment (for 8 
h) and dual luc reporter assay. Statistical analysis was performed between WT TRIM56 
and vector or mutant TRIM56 after poly-I:C treatment. Double asterisks denote that 
statistical differences exist with a P value of < 0.01. N.S., not statistically significant. 
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Figure 5-4. Putative phosphorylation on TRIM56’s C-terminal serines S471, S475 
and S710 is essential for its positive regulation of TLR3-mediated signaling 
pathway. 
(A) Schematic representation of four conserved putative phosphorylation sites in human 
TRIM56 (S469, S471, S475 and S710) and mouse TRIM56. (B) Immunoblot analysis of 
the expression of vectors encoding WT TRIM56-V5 and its S710A, S710D and Δ693-
750 mutants (using mouse anti-V5 mAb) in HEK293 cells. Actin serves as a loading 
control. (C) HEK293-TLR3 cells were co-transfected with an empty vector or plasmids 
encoding WT or mutant hT56 (left part) or mT56 (upper right part), as well as internal 
control plasmid pRL-TK and reporter plasmid IFN-β-luc, followed by mock treatment or 
treatment with poly-I:C for 8 h. Dual luc reporter assay was then performed to measure 
the promoter activation. (Lower right) Immunoblot analysis of expression of the vectors 
encoding WT mT56-V5 and its mutant S689A. (D) (Left) Immunoblot analysis of 
expression level of endogenous TRIM56 (using rabbit anti-TRIM56 pAb) in HeLa cells 
or those stably transduced with a non-targeting, scrambled control shRNA (Ctrl), or 
HeLa-shT56 cell clones stably transduced with a TRIM56 shRNA (#093) which 
specifically targets the 3’UTR region of human TRIM56. Asterisk denotes a nonspecific 
band. (Right) HeLa-shT56 cells (clone #9) and its knockdown control cells (Ctrl) were 
co-transfected with an empty vector or vectors encoding WT or mutant TRIM56 as well 
as internal control plasmid pRL-TK and reporter plasmid IFN-β-luc, followed by mock 
treatment or treatment with poly-I:C for 8 h. Dual luc reporter assay was then performed 
to measure the promoter activation. (E) (upper part) Human hepatoma Huh7.5-TLR3 
cells ectopically expressing TLR3 were co-transfected with an empty vector or vectors 
encoding WT or mutant TRIM56 as well as internal control plasmid pRL-TK and 
reporter plasmid IFN-β-luc, followed by mock treatment or treatment with poly-I:C (for 8 
h) and dual luc reporter assay. (Lower part) Immunoblot analysis of the expression of the 
vectors encoding WT TRIM56-V5 and its S469A, S471A or S475A single mutant and 
S469A+S471A+S475A triple mutant (using mouse anti-V5 mAb) in HEK293 cells. 
Statistical analysis was performed between WT TRIM56 and vector or mutant TRIM56 
after poly-I:C treatment. Single, double and triple asterisks denote that statistical 
differences exist with a P value of < 0.05, < 0.01 and < 0.001, respectively. N.S., not 
statistically significant. 
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(clone #9) compared with that in the knockdown control (Ctrl) cells. In HeLa-shT56 093 
(clone #9) cells, while the phospho-mimetic TRIM56-S710D mutant exhibited 
comparable activity to WT TRIM56 in promoting TLR3 signaling, the TRIM56-S710A 
mutant (P < 0.05) had a significantly impaired activity. Similar results were obtained in 
control HeLa cells.  
 
Further, alanine screening mutagenesis (Figure 5-4E) suggested the S471A or S475A 
single mutant or S469A+S471A+S475A triple mutant failed to enhance TLR3 signaling 
(P < 0.05, < 0.001, and 0.01, respectively), while the S469A mutant was only slightly 
impaired for such ability (statistically insignificant when compared with WT TRIM56), 
supporting a role for putative phosphorylation of TRIM56 at S471 and S475 in promoting 
TLR3 signaling. These findings show the importance of putative phosphorylation sites 
S710, S471 and S475 in TRIM56-mediated up-regulation of TLR3 signaling. 
 
 
Alanine Substitutions on the Important TRIM56’s Putative Phosphorylation Sites 
and Deletion of the Coiled-coil Domain Undermine the TRIM56-mediated 
Enhancement of TLR3-dependent Antiviral Response 
 
I have shown that TRIM56 mutants on the putative phosphorylation sites and the 
coiled-coil domain impair TLR3-mediated IFN-β promoter activation, which is critical 
for establishment of an antiviral state (39). Next I directly determined the impact of these 
mutations on TLR3-mediated establishment of an antiviral state. To this end, I 
established HEK293-FIT-derived cell lines with tet-inducible expression of HA-TRIM56 
with alanine mutations on TRIM56’s putative phosphorylation sites using the strategy we 
chose to create the 293-FIT-T56 cell line. These include cell lines with tet-inducible 
expression of S469A, S471A, S475A or S710A single mutant, and 
S469A+S471A+S475A triple mutant, respectively. As shown in Figure 5-5A, there was 
negligible expression of mutant HA-TRIM56 when these cell lines were cultured in the 
absence of tet (Figure 5-5A, odd-numbered lanes, data for S710A (-tet) not shown), 
while robust expression of mutant HA-TRIM56 of comparable levels to WT TRIM56 in 
HEK293-FIT-T56 cells, was detected in tet-containing medium (Figure 5-5A and lower 
panel of Figure 5-5B (including data for S710A +tet cells)). Next, HEK293-FIT-derived 
cells conditionally expressing WT and mutant HA-TRIM56 with (+tet) or without (-tet) 
tet were reconstituted with Flag-TLR3 by transient transfection of a TLR3-encoding 
plasmid (Figure 5-5B, lower), followed by poly-I:C stimulation to induce an antiviral 
state and then VSV-luc challenge. In mock-treated cells, regardless of cell type and tet 
addition status, VSV-luc replicated with similar efficiency as illustrated by the virus-
encoded luc activity (Figure 5-5B, upper), which is in line with our previous finding that 
TRIM56 itself had no influence on VSV replication (34). Poly-I:C stimulation induced an 
antiviral state in the cells without tet (-tet, i.e., no induction of WT or mutant TRIM56) to 
similar extent among WT and mutant TRIM56 cell lines, resulting in a ~75% reduction in 
VSV-luc replication compared with unstimulated cells. By contrast, WT TRIM56 
induction in 293-FIT-T56 (+tet) cells exhibited significantly (P < 0.05) more inhibition of 
VSV-luc replication (88%), consistent with our earlier finding that TRIM56 potentiates 
the dsRNA-stimulated, TLR3-dependent antiviral response (39). This phenomenon was 
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Figure 5-5. TRIM56’s coiled-coil domain and C-terminal putative 
phosphorylation sites S710, S471 and S475 are important for the establishment of an 
antiviral state by TLR3 ligand. 
(A) Generation of HEK293-FIT-derived cells that conditionally express individual 
TRIM56 mutants on the putative phopho-sites in a tet-inducible manner. Immunoblot 
analysis of expression of WT HA-TRIM56 and various mutant TRIM56 (using mouse 
anti-HA mAb) in 293-FIT-T56 WT/Mut cells with (+tet) or without (-tet) tet treatment 
for 48 h. Actin serves as a loading control. (B) (Upper) HEK293-FIT-derived cells 
conditionally expressing WT HA-TRIM56 and its mutants at the indicated putative 
phospho-sites with (+tet) or without (-tet) tet, were reconstituted with TLR3 and mock-
stimulated or stimulated by poly-I:C, followed by infection with VSV-luc (MOI = 0.1). 
At 6 h postinfection, cells were lysed for firefly luciferase assay. (Lower) Immunoblot 
analysis of expression of the induced WT and mutant HA-TRIM56 (using mouse anti-HA 
mAb) and reconstituted Flag-tagged TLR3 (using mouse anti-flag mAb) in the tested 
293-FIT-T56 WT/Mut cells before VSV-luc infection. (C) HEK293-FIT-derived cells 
conditionally expressing WT HA-TRIM56 and its coiled-coil domain deletion mutant 
(Δcoiled-coil) with (+tet) or without (-tet) tet, were reconstituted with TLR3 and mock-
stimulated or stimulated by poly-I:C, followed by infection with VSV-luc (MOI = 0.1). 
At 4 h postinfection, cells were lysed for firefly luciferase assay. (Lower) Immunoblot 
analysis of expression of the induced WT HA-TRIM56 and its ΔCoiled-coil mutant 
(using mouse anti-HA mAb) in the tested 293-FIT-T56 WT/ΔCoiled-coil cells before 
VSV-luc infection.  Statistical analysis was performed between poly-I:C-treated -tet and 
+tet cells. Single and double asterisks denote that statistical differences exist with a P 
value of < 0.05 and < 0.01, respectively. N.S., not statistically significant. 
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also found in TRIM56-S469A expressing cells (+tet) which had 85% decrease in VSV-
luc replication, suggesting that TRIM56-S469A retains the ability to promote the 
TRIM56-TLR3-dependent antiviral response. On the contrary, expression of Δ693-750, 
S471A, S475A, S469A+S471A+S475A or S710A mutants failed to promote a poly-I:C-
stimulated, TRIM56-TLR3-dependent antiviral response. There was no further 
statistically significant decrease in VSV-luc replication in poly-I:C-treated, +tet mutant 
cells as compared with poly-I:C-treated, –tet mutant cells (Figure 5-5B, upper). This 
could also be said for cells conditionally expressing the Δcoiled-coil mutant, since the 
293-FIT- Δcoiled-coil cells cultured in the presence of tet (+tet) lost the ability to 
enhance poly-I:C-stimulated antiviral response against VSV-luc (Figure 5-5C). These 
observations show TRIM56’s putative phosphorylation sites S471, S475 and S710 and its 
coiled-coil domain play critical roles in promoting TLR3-dependent antiviral responses. 
 
 
TRIM56’s Putative Phosphorylation Site S710 on the C-terminus, but Not the 
Coiled-coil Domain, Is Critical for Its Association with TRIF 
 
I next sought to characterize the mechanism(s) by which TRIM56’s putative 
phosphorylation site and coiled-coil domain help TRIM56 to promote TLR3 signaling. 
TRIM56 was reported to promote TLR3 signaling by forming a complex with TRIF (39). 
Given the fact that S710 falls into the region (aa 621-750) responsible for its association 
with TRIF, I asked if this putative phosphorylation site is important for TRIM56-TRIF 
interaction. Co-IP experiments showed that the S710A mutant abolished the TRIM56-
TRIF interaction similar to the Δ693-750 TRIM56 mutant (Figure 5-6A). Since the 
S710A mutant lost the ability to augment poly-I:C-induced IFN transcription  
(Figure 5-4) and host antiviral response (Figure 5-5B), I concluded that TRIM56’s 
putative phosphorylation site S710 may affect the TRIM56 interaction with TRIF. Next I 
asked if the coiled-coil domain, which was found to be important for positive regulation 
of TLR3 signaling was also indispensable for TRIM56-TRIF association. As shown in 
the co-IP experiment with 293-FIT-T56 WT/Mut cells (Figure 5-6B), the ΔCoiled-coil 
mutant retained the ability to form a complex with TRIF, suggesting that the coiled-coil 
domain is not required for the TRIM56-TRIF association. Interestingly, this experiment 
also showed that aa 355-433 does not mediate the interaction with TRIF either, since the 
Δ355-433 mutant can still interact with TRIF. 
 
 
Discussion 
 
It has been shown that TRIM56 possesses the ability to promote TLR3-mediated 
IRF3-dependent antiviral signaling and IFN induction. Interestingly, TRIM56 
knockdown suppressed TLR3-mediated induction of RANTES and IP-10 in hepatitis C 
virus (HCV) infected hepatoma cells (39), chemokines that are under coordinate control 
of NF-κB and IRF3 (84). The present study directly demonstrates that TRIM56 positively 
regulates TLR3-mediated NF-κB activation (Figure 5-1B), in addition to its effect on 
IRF3 activation (39). These data suggest that TRIM56 acts at a level prior to the 
bifurcation of IRF3 and NF-κB, and are consistent with our previous data showing that  
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Figure 5-6. TRIM56’s putative phospho-site S710, but not its coiled-coil domain, 
is important for its interaction with TRIF. 
(A) Co-IP experiment in HEK293 cells co-expressing Flag-TRIFSA and WT TRIM56-V5 
or various mutant TRIM56-V5. Cell lysates were immunoprecipitated (IP) with anti-V5, 
followed by immunoblotting (IB) with anti-Flag or anti-V5. The right blot showed 
expression of the various TRIM56-V5 (WT or mutant) and Flag-TRIFSA in cell lysates. 
(B) Co-IP experiment in HEK293-FIT-T56 WT/mut cells co-expressing Flag-TRIFSA and 
WT or various mutant HA-TRIM56 (by addition of tet (+tet)). Cell lysates were 
immunoprecipitated (IP) with anti-TRIM56, followed by immunoblotting (IB) with anti-
Flag or anti-HA. The bottom blot showed expression of the various HA-TRIM56 (WT or 
mutant) and Flag-TRIFSA in cell lysates. 
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TRIM56 likely promotes TLR3 signaling by associating with TRIF. As additional 
evidence supporting this notion, we show here that endogenous TRIM56 and TRIF 
proteins formed a complex at an early stage after TLR3 engagement, prior to induction of 
ISG56, an IRF3-target gene (Figure 5-1). The observation that TRIM56 promotes both 
IRF3 and NF-κB arms of TLR3 signaling suggests that it may regulate IFN antiviral 
responses as well as inflammatory chemokine/cytokine responses activated through this 
innate immune pathway. 
 
In this study, I have comprehensively dissected the molecular determinants governing 
the ability of TRIM56 to positively regulate the TLR3 signaling pathway. I found that 
TRIM56’s coiled-coil domain and an extended C-terminal portion (aa 431-610) are 
critical for promoting TLR3 signaling (Figures 5-2 and 5-3), while the B-box and a 
central region downstream of the Coiled-coil domain (aa 355-433) are not. Within the 
important C-terminal region, I identified three conserved, putative phosphorylation sites, 
i.e., S471, S475 and S710, as indispensable for TRIM56-mediated up-regulation of TLR3 
signaling (Figure 5-4). Importantly, these findings were observed in different cell types 
and expression/silencing systems. Moreover, the effects on IFN promoter activation were 
recapitulated by VSV-Luc-based assay directly gauging TLR3-dependent establishment 
of an antiviral state. (Figure 5-5).  Together, our data reveal novel insights into the 
mechanism of TRIM56 augmentation of the TLR3-dependent antiviral response and 
highlights a role for TRIM56 scaffolding and phosphorylation in positive regulation of 
TLR3 signaling. 
 
In the extended C-terminal region now identified to be required for up-regulation of 
TLR3 signaling, aa 515-610 account for half of the NHL-like repeats of TRIM56 (aa 
497-754, Figure 4-9), a barrel-like β-propeller structure which may be important for 
protein-RNA or protein-protein interaction (36). On the other hand, I found that putative 
phosphorylation sites S471 and S475 within aa 431-519 and S710 on the C-terminal end 
are important for TRIM56 to potentiate TLR3-dependent IFN-β promoter activation and 
establishment of an antiviral state (Figures 5-4 and 5-5). Furthermore, S710A completely 
abolished TRIM56-TRIF interaction (Figure 5-6).  Others studies of post-translational 
modification of TRIMs were focused on ubiquitination due to the fact that TRIMs bear 
E3 ligase activity and they tend to catalyze the self-reactions that are believed to be 
important for their functions (29,34,37). Recently tyrosine phosphorylation of the E3 
ubiquitin ligase TRIM21 has been reported to be critical for TLR3/4-mediated positive 
regulation of IRF3 activation and IFN induction (85). Interestingly, ProtScale analysis 
indicates that aa 425-475 of TRIM56 is a highly hydrophilic region for TRIM56, which is 
in agreement with our prediction that phosphorylation occurs on S471 or/and S475.  
 
This study also demonstrates that the coiled-coil domain is indispensable for TRIM56 
promotion of TLR3 signaling (Figures 5-2, 5-3 and 5-5). The coiled-coil domains of 
TRIMs have been reported to mediate dimerization of TRIM molecules (66). 
Interestingly, I observed that a coiled-coil domain deletion mutant (ΔCoiled-coil) was 
still able to associate with TRIF (Figure 5-6B). This suggests that the TRIM56-TRIF 
interaction does not require TRIM56 dimerization. Rather, I propose that the TRIM56 
coiled-coil domain may serve as a scaffold that recruits and interacts with other important 
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signaling components, thereby accelerating signal transduction. However, further 
experiments are needed to confirm that the coiled-coil domain is indispensable for 
TRIM56 oligomerization. Also, further investigation is still needed to clarify the previse 
role of the TRIM56 coiled-coil domain and its possible scaffolding function in positive 
regulation of TLR3 signaling. 
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CHAPTER 6.    DISCUSSION 
 
 
The Distinct Domain Requirements for TRIM56’s Anti-flaviviruses and Anti-
HCoV-OC43 Actions May Reflect Different Molecular Mechanisms That TRIM56 
Adopts to Restrict Different Positive-strand RNA Viruses 
 
In this body of work, I have demonstrated that human TRIM56 is an antiviral host 
factor against diverse positive-strand RNA viruses. Specifically, TRIM56 exhibits 
antiviral activities against two medically important flaviviruses (YFV and DENV2) and a 
human coronavirus (HCoV-OC43) (Figures 3-1 and 3-2). Further, I have shown that the 
E3 ligase activity is a shared requirement for the antiviral actions of TRIM56 against the 
two flaviviruses and HCoV-OC43, and that while dispensable for restricting HCoV-
OC43, the integrity of the C-terminal portion of TRIM56 is additionally required for the 
anti-flavivirus functions (Figures 3-6, 3-7 and 3-9). I also found that TRIM56 suppresses 
intracellular viral RNA replication of yellow fever and dengue viruses but may target the 
packaging or release steps in HCoV-OC43 life cycle (Figure 3-10).  
 
The findings concerning the differing domain requirements for the novel antiviral 
actions of TRIM56 suggest differences in the antiviral mechanisms against different 
viruses. By virtue of the E3 ligase activity, TRIM56 might modulate posttranslational 
modification(s) of one or more viral proteins and host factors to suppress positive-strand 
RNA virus replication (34). Given its broad antiviral activities against positive-strand 
RNA viruses, I favor the hypothesis that host factors are involved. The target proteins for 
TRIM56 E3 ligase during infections with flaviviruses (YFV and DENV) and HCoV-
OC43 will need further studies. TRIM56 promotes ubiquitination (34), the best-known 
enzymatic activity for most TRIMs (29,31,77,86). It is not known, however, how this 
modification of the target proteins may be responsible for the antiviral effects, including, 
but not limited to, promoting their degradation or altering their intracellular trafficking. It 
is also possible that TRIM56 antiviral function works by promoting Ub-like 
modifications such as sumoylation and ISGylation, as demonstrated with TRIM28 and 
TRIM25 (87,88).  
 
Moreover, the dichotomy in the molecular determinants governing TRIM56’s anti-
flaviviruses and anti-HCoV-OC43 functions is that the former is additionally dependent 
upon TRIM56’s C-terminal portion. I speculate that this might accommodate the different 
replication strategies between flaviviruses and coronaviruses. Given that the C-terminal 
region mediates the interactions of TRIM56 with STING, N-terminal protease of BVDV, 
and TRIF (34,39,58), protein-protein interactions via the C-terminal portion may 
participate in TRIM56’s antiviral actions against YFV and DENV2. Besides facilitating 
presentation of specific substrate to E2 conjugating enzyme, TRIM56’s C-terminal part 
may form a complex with flaviviral protein(s) and/or perhaps flavivirus-specific host 
factors in the cytoplasm, in ways that hinder viral RNA replication. I favor the notion that 
host factors are likely targeted by TRIM56 given that we did not find any BVDV 
replicase proteins to interact with TRIM56 in a previous study (34). In contrast to the 
proposed canonical TRIM E3 ligase model in which the RING domain and C-terminal 
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portion work in concert (29,65), the E3 ligase activity as the sole prerequisite for 
TRIM56’s anti-HCoV-OC43 effect might suggest a reliance on some other co-factors to 
accomplish substrate presentation in lieu of TRIM56’s C-terminal portion, which will 
require further investigation. Obviously, identifying the interaction partners of TRIM56 
holds the key to understanding the exact antiviral mechanisms. Studies to this end are 
underway in our laboratory. 
 
 
Possible Molecular Mechanisms Underlying Which C-terminal End of TRIM56 
Undermines Influenza Virus RNA Replication 
 
In this body of work, I have demonstrated that TRIM56 compromised propagation of 
both influenza A and B viruses by suppressing viral RNA replication (Figures 4-1, 4-2, 
4-6 and 4-7), which only requires TRIM56’s C-terminal 63 residues (Figures 4-3 and 4-
4). Moreover, expression of this short C-terminal segment (CTT135 or CTT63) restricts 
influenza viruses as effectively as WT TRIM56 (Figure 4-5). In line with its function in 
curbing influenza virus RNA replication, which takes place in the nucleus, I found that a 
fraction of TRIM56 moved into the nucleus after influenza virus infection (Figure 4-8). 
This is also true for CTT63. These findings provide insights into the mechanisms by 
which TRIM56 curbs these medically-important negative-strand RNA viruses. 
 
Precisely how the C-terminal tail portion of TRIM56 impedes influenza viral RNA 
synthesis is unclear. The C-terminal region of TRIM56 has been shown to interact with 
viral and cellular proteins imparting various biological functions, as exemplified by the 
TRIM56 association with the N-terminal protease of BVDV (34), TRIF (39), and STING 
(58). In light of this, TRIM56 may associate with a component(s) of viral RNP or a 
proviral host factor(s) recruited to the RNP complex, interfering with the partner’s role in 
viral RNA synthesis. This notion, to some extent, is supported by the confocal data 
(Figure 4-8), which suggest co-localization of TRIM56 with NP or M proteins after IAV 
infection. In addition, in co-IP assays performed in HEK293-TLR3-YFP cells 
overexpressing Flag-HA-tagged TRIM56 (293-T3Y-FH-TRIM56), and I observed that 
TRIM56 formed a complex with NP during IAV infection (data not shown). More 
experiments are still required to confirm the TRIM56-NP interaction and determine its 
biological consequences. 
 
However, another possibility is that TRIM56 interacts with influenza viral RNAs, 
altering their incorporation into the viral transcription/replication complex and/or their 
stability. Though TRIM56 was not previously identified in influenza virus particles (89), 
the possibility of TRIM56 associating with mRNAs of influenza virus or proviral cellular 
factors and regulating their translation also cannot be ruled out. Intriguingly, the C-
terminal region of TRIM56 (residues 521-748, see Figures 4-5A and 4-9) exhibits 
sequence homology with NHL repeats based on a search of the NCBI conserved domain 
database. Sequence alignment of TRIM56 with several well-characterized TRIM-NHL 
proteins, TRIM2, TRIM3, TRIM32 and TRIM71, also showed conservation on numerous 
consensus residues shaping the NHL repeats (Figure 4-9) (75,76). The NHL repeats fold 
into a barrel-like β-propeller structure, whose partial surface is positively charged and 
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could directly interact with the phosphate backbone of RNA, which is negatively 
charged. As an example, TRIM71 can associate with miRNAs and mRNAs and regulate 
translation and mRNA metabolism (90). Obviously, further investigation is required to 
elucidate how TRIM56 hinders influenza virus RNA synthesis, knowledge of which will 
provide new insights into factors and molecular interactions controlling this vital step in 
influenza virus life cycle.  
 
 
Dissect the Molecular Mechanisms Dictating TRIM56-mediated Positive Regulation 
of the TLR3 Signaling Pathway 
 
In this body of work, I studied the TRIM56 molecular determinants that govern the 
positive regulation of TLR3-mediated IRF3 and NF-κB activation. Confirming our 
previous finding that TRIM56 formed a complex with TRIF in an overexpression setting 
(39), I found that an association of endogenous TRIM56 and TRIF proteins occurs at an 
early stage after TLR3 engagement (Figures 5-1), prior to dsRNA-induced ISG56 
expression through this pathway. Detailed domain mapping suggests that TRIM56’s 
coiled-coil domain and aa 431-610 were required for augumentation of TLR3 signaling 
(Figures 5-2 and 5-3). Further, three conserved, putative phosphorylation sites S471, 
S475 and S710 were found to be important for up-regulation of TLR3-mediated signaling 
(Figure 5-4). Concordant with this, I demonstrated that the putative phosphorylation sites 
S471, S475 and S710 as well as the coiled-coil domain are essential for TLR3-mediated 
establishment of an antiviral state (Figure 5-5). Given that the coiled-coil domain confers 
TRIMs with scaffolding function and that post-translational modification, such as 
phosphorylation, play an important role in regulating protein function (34,66,85), our 
data suggest that further studies of TRIM56’s scaffolding function and phosphorylation 
status at S471, S475 and S710 after TLR3 engagement are important to better understand 
the precise molecular mechanisms by which TRIM56 positively regulateTLR3 signaling. 
 
Although TLR3 contributes to sensing viral invasion and facilitating the 
establishment of an antiviral state during certain viral infections, excessive and 
unregulated immune signaling through this PRR may lead to overwhelmingly harmful 
inflammatory responses detrimental to the host (4,84). I have demonstrated that TRIM56 
promotes TLR3-mediated NF-κB activation, supporting that TRIM56 might play a role in 
inflammatory cytokine/chemokine responses. It would be interesting to examine whether 
TRIM56-regulated TLR3 signaling leads to heightened up-regulation of pro-
inflammatory cytokines/chemokines, which are NF-κB-dependent. Another intriguing 
question is how host cells tune down TRIM56-promoted TLR3 signaling after PAMPs 
have been sensed and this pathway has been activation. Indeed, the dynamic interaction 
between endogenous TRIM56 and TRIF protein (Figure 5-1C) suggests the association 
between TRIM56 and the TLR3 adaptor protein may be tightly regulated.  
 
To further investigate exactly how the scaffolding function conferred on TRIM56 by 
its coiled-coil domain contributes to positive regulation of TLR3 signaling, it would be 
worthwhile to correlate TRIM56’s scaffolding function with its ability to promote the 
TLR3 signaling. This aspect could be examined by determining whether the ΔCoiled-coil 
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mutant that fails to promote TLR3 signaling loses the scaffolding function. To this end, I 
have performed native PAGE and subsequent immunoblot analysis demonstrating that 
WT TRIM56 molecules self-associate to form homodimers but the ΔCoiled-coil mutant 
failed to do so (data not shown). Moreover, to directly demonstrate that the ΔCoiled-coil 
mutant loses the ability to associate with each other, V5-tagged, WT TRIM56 or 
ΔCoiled-coil mutant will be co-transfected into HEK293 cells with GFP-tagged WT 
TRIM56, followed by IP using anti-V5 and immunoblot analysis for GFP-tagged WT 
TRIM56. Further, key residues in TRIM56’s coiled-coil domain, which are critical for 
self-association or oligomerization, should be identified and tested for their necessity for 
TRIM56-mediated augmentation of TLR3 signaling. Recent crystallographic and 
biochemical analyses have demonstrated that L252 and E256 in the TRIM25 coiled-coil 
domain are two important residues stabilizing the elongated antiparallel hairpin dimer 
formed by the coiled-coil domains (66). Interestingly, that leucine residue is well 
conserved among different TRIMs including TRIM56, in which it is at 266 position 
(L266). In the future, it will be interesting to determine the effect of L266 mutation on 
TRIM56 dimerization and TRIM56-mediated enhancement of TLR3 signaling.. 
 
My data suggest that putative phosphorylations on S471, S475 and S710 may be 
important for the ability of TRIM56 to promote TLR3 signaling. Obviously, directly 
examining this post-translational modification at these residues is warranted. Along this 
line, our attempts to detect phosphorylation of TRIM56 at S471, S475 and S710 
following TLR3 engagement by performing IP using anti-TRIM56 antibody followed by 
immunoblot analysis using anti-phosphoserine antibody have thus far failed, due to the 
poor specificity and sensitivity of the available anti-phosphoserine antibodies. To solve 
this problem, we have custom-made phospho-specific antibody recognizing p-S471 or p-
S475 and experiments with these antibodies are under way. 
 
 
Conclusion 
 
 I unveiled the spectrum and specificity of the antiviral activities of TRIM56 against 
distinct positive-strand RNA viruses such as yellow fever and dengue viruses as well as 
human coronavirus-OC43, broadening the scope of the roles this TRIM plays in antiviral 
immunity (Figures 3-1 and 3-2). Equally important, I showed that TRIM56 
accommodates these previously unrecognized antiviral functions via overlapping and 
distinct molecular determinants, which dictate shared and disparate antiviral actions 
(Figures 3-6, 3-7 and 3-9). These new revelations provide novel insights into the detailed 
antiviral mechanisms of TRIM56 (Figure 3-10) and raise the possibility of targeting this 
TRIM for development of broad antivirals. 
 
Furthermore, I identified TRIM56 as an intrinsic cellular restriction factor of influenza 
A and B viruses (Figures 4-1 and 4-2) and described a novel, E3 ligase-independent 
antiviral mechanism that targets influenza viral RNA synthesis (Figures 4-3 through 4-7). 
Our data delineate novel antiviral properties of TRIM56 against orthomyxoviruses and 
may open new avenues to developing influenza antivirals. 
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Last but not least, I confirmed that TRIM56 is a positive regulator of TLR3-mediated 
NF-κB signaling (Figure 5-1) and demonstrated that a large C-terminal portion and the 
coiled-coil domain of TRIM56 are both essential for promoting TLR3 signaling  
(Figures 5-2 and 5-3). Further, I demonstrated a requirement for 3 putative 
phosphorylation sites, i.e., S471, S475 and S710 for TRIM56-mediated augmentation of 
TLR3 signaling. S710 may be an important binding site for TRIM56-TRIF interaction 
(Figures 5-4 through 5-6), or phosphorylation at this residue is critical for maintaining 
the proper conformation of TRIM56 C-terminus. Furthermore, I demonstrated that 
TRIM56’s coiled-coil domain is indispensable for TLR3-mediated establishment of an 
antiviral state (Figure 5-5), confirming the signaling data. Together, my data revealed 
novel insights into the mechanism dictating TRIM56’s augmentation of TLR3-dependent 
antiviral response and highlighted role for TRIM56 scaffolding and phosphorylation in 
positive-regulation of TLR3 signaling. 
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